1
|
Vukusic S, Ionescu I, Cornu C, Bossard N, Durand-Dubief F, Cotton F, Durelli L, Marignier R, Gignoux L, Laplaud DA, Moreau T, Clavelou P, De Seze J, Debouverie M, Brassat D, Pelletier J, Lebrun-Frenay C, Le Page E, Castelnovo G, Berger E, Hautecoeur P, Heinzlef O, Trojano M, Patti F, Baulieu EE, Remontet L, El-Etr M. Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study. Mult Scler 2020; 27:1458-1463. [DOI: 10.1177/1352458520978218] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background: Sex steroids could explain the course of multiple sclerosis (MS) in pregnancy. Objective: To compare the annualized relapse rate (ARR) 12 weeks post-partum in women treated with nomegestrol acetate (NOMAc) and 17-beta-estradiol (E2) versus placebo. Methods: POPARTMUS is a randomized, proof-of-concept trial in women with MS, receiving oral NOMAc 10 mg/day and transdermal estradiol 75 µg/week, or placebo. Results: Recruitment was stopped prematurely due to slow inclusions ( n = 202). No treatment effect was observed on ARR after 12 weeks (sex steroids = 0.90 (0.58–1.39), placebo = 0.97 (0.63–1.50) ( p = 0.79)). Conclusion: POPARTMUS failed showing efficacy of a NOMAc–E2 combination in preventing post-partum relapses.
Collapse
Affiliation(s)
- Sandra Vukusic
- Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation et Fondation Eugène Devic EDMUS pour la Sclérose en Plaques, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon-Bron, France/Centre des Neurosciences de Lyon, INSERM 1028 et CNRS UMR5292, Observatoire Français de la Sclérose en Plaques, Lyon, France/Université Claude Bernard Lyon 1, Villeurbanne, France
| | - Iuliana Ionescu
- Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation et Fondation Eugène Devic EDMUS pour la Sclérose en Plaques, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon-Bron, France
| | - Catherine Cornu
- Centre d’Investigation Clinique INSERM1407, Hospices Civils de Lyon, Lyon, France/Service de Pharmaco-toxicologie, Lyon, France/UMR5558, Claude Bernard University, Lyon, France
| | - Nadine Bossard
- Hospices Civils de Lyon, Pôle Santé Publique, Service de Biostatistique–Bioinformatique, Lyon, France/Université de Lyon, Université Lyon 1, CNRS, UMR 5558, Laboratoire de Biométrie et Biologie Évolutive, Équipe Biostatistique-Santé, Villeurbanne, France
| | - Françoise Durand-Dubief
- Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation et Fondation Eugène Devic EDMUS pour la Sclérose en Plaques, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon-Bron, France/CREATIS, UMR 5220 CNRS & U1044 Inserm, Université Claude Bernard Lyon1, Université de Lyon, Villeurbanne, France
| | - François Cotton
- CREATIS, UMR 5220 CNRS & U1044 Inserm, Université Claude Bernard Lyon1, Université de Lyon, Villeurbanne, France/Service de Radiologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Lyon, France
| | - Luca Durelli
- Clinical and Biological Sciences Department, University of Torino, Turin, Italy
| | - Romain Marignier
- Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation et Fondation Eugène Devic EDMUS pour la Sclérose en Plaques, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon-Bron, France/Université Claude Bernard Lyon 1, Villeurbanne, France/Centre des Neurosciences de Lyon, INSERM 1028 et CNRS UMR5292, Fluid team, Lyon, France
| | - Laurence Gignoux
- Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation et Fondation Eugène Devic EDMUS pour la Sclérose en Plaques, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon-Bron, France
| | - David-Axel Laplaud
- CHU de Nantes, Service de Neurologie & CIC015 INSERM, Nantes, France, INSERM CR1064, Nantes, France
| | - Thibault Moreau
- Department of Neurology, EA4184, University Hospital of Dijon, Dijon, France
| | - Pierre Clavelou
- Service de Neurologie, CHU Clermont-Ferrand, Clermont-Ferrand, France/Inserm U1107, Clermont Université, Université d’Auvergne, Neuro-Dol, Clermont-Ferrand, France
| | - Jérôme De Seze
- Department of Neurology and Clinical Investigation Center, CHU de Strasbourg, INSERM, Strasbourg, France
| | - Marc Debouverie
- EA 4360 Apemac, Lorraine University, Nancy, France/Department of Neurology, Nancy University Hospital, Nancy, France
| | - David Brassat
- Pôle Neurosciences, CHU Toulouse Purpan, Toulouse, France/INSERM U1043-CNRS UMR 5282, Université Toulouse III, Toulouse, France
| | - Jean Pelletier
- Aix Marseille Univ, APHM, Hôpital de la Timone, Pôle de Neurosciences Cliniques, Service de Neurologie, Marseille, France
| | | | - Emmanuelle Le Page
- Clinical Neuroscience Centre, CIC-P 1414 INSERM, Rennes University Hospital, Rennes, France
| | | | - Eric Berger
- Department of Neurology, CHU Besançon, Besançon, France
| | - Patrick Hautecoeur
- Service de Neurologie, Groupe Hospitalier de l’Institut Catholique de Lille, Lille Cedex, France
| | - Olivier Heinzlef
- Neurology Department, Hospital of Poissy-St-Germain en Laye, Paris, France
| | - Maria Trojano
- Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, Italy
| | - Francesco Patti
- Department of Medical and Surgical Sciences, and Advanced Technologies, GF Ingrassia, Multiple Sclerosis Center, University of Catania, Catania, Italy
| | | | - Laurent Remontet
- Hospices Civils de Lyon, Pôle Santé Publique, Service de Biostatistique–Bioinformatique, Lyon, France/Université de Lyon, Université Lyon 1, CNRS, UMR 5558, Laboratoire de Biométrie et Biologie Évolutive, Équipe Biostatistique-Santé, Villeurbanne, France
| | | |
Collapse
|
2
|
Iannello A, Rolla S, Maglione A, Ferrero G, Bardina V, Inaudi I, De Mercanti S, Novelli F, D'Antuono L, Cardaropoli S, Todros T, Turrini MV, Cordioli C, Puorro G, Marsili A, Lanzillo R, Brescia Morra V, Cordero F, De Bortoli M, Durelli L, Visconti A, Cutrupi S, Clerico M. Pregnancy Epigenetic Signature in T Helper 17 and T Regulatory Cells in Multiple Sclerosis. Front Immunol 2019; 9:3075. [PMID: 30671056 PMCID: PMC6331474 DOI: 10.3389/fimmu.2018.03075] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2018] [Accepted: 12/12/2018] [Indexed: 12/22/2022] Open
Abstract
Increasing evidence supports the anti-inflammatory role of estrogens in Multiple Sclerosis (MS), originating from the observation of reduction in relapse rates among women with MS during pregnancy, but the molecular mechanisms are still not completely understood. Using an integrative data analysis, we identified T helper (Th) 17 and T regulatory (Treg) cell-type-specific regulatory regions (CSR) regulated by estrogen receptor alpha (ERα). These CSRs were validated in polarized Th17 from healthy donors (HD) and in peripheral blood mononuclear cells, Th17 and Treg cells from relapsing remitting (RR) MS patients and HD during pregnancy. 17β-estradiol induces active histone marks enrichment at Forkhead Box P3 (FOXP3)-CSRs and repressive histone marks enrichment at RAR related orphan receptor C (RORC)-CSRs in polarized Th17 cells. A disease-associated epigenetic profile was found in RRMS patients during pregnancy, suggesting a FOXP3 positive regulation and a RORC negative regulation in the third trimester of pregnancy. Altogether, these data indicate that estrogens act as immunomodulatory factors on the epigenomes of CD4+ T cells in RRMS; the identified CSRs may represent potential biomarkers for monitoring disease progression or new potential therapeutic targets.
Collapse
Affiliation(s)
- Andrea Iannello
- Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
| | - Simona Rolla
- Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
| | - Alessandro Maglione
- Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
| | - Giulio Ferrero
- Department of Computer Science, University of Turin, Turin, Italy
| | - Valentina Bardina
- Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
| | - Ilenia Inaudi
- Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
| | - Stefania De Mercanti
- Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
| | - Francesco Novelli
- Department of Molecular Biotechnology and Healthy Sciences, University of Turin, Turin, Italy
| | - Lucrezia D'Antuono
- Obstetric and Gynecologic Department, OIRM-Sant'Anna Hospital, Città della Salute e della Scienza, Turin, Italy
| | | | - Tullia Todros
- Department of Surgical Sciences, University of Turin, Turin, Italy
| | - Maria Vittoria Turrini
- Multiple Sclerosis Center, Ospedali Civili di Brescia, Montichiari Hospital, Montichiari, Italy
| | - Cinzia Cordioli
- Multiple Sclerosis Center, Ospedali Civili di Brescia, Montichiari Hospital, Montichiari, Italy
| | - Giorgia Puorro
- Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples Federico II, Naples, Italy
| | - Angela Marsili
- Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples Federico II, Naples, Italy
| | - Roberta Lanzillo
- Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples Federico II, Naples, Italy
| | - Vincenzo Brescia Morra
- Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples Federico II, Naples, Italy
| | | | - Michele De Bortoli
- Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
| | - Luca Durelli
- Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
| | | | - Santina Cutrupi
- Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
| | - Marinella Clerico
- Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
| |
Collapse
|
3
|
Lavie C, Rollot F, Durand-Dubief F, Marignier R, Ionescu I, Casey R, Moreau T, Tourniaire P, Hutchinson M, D’Hooghe MB, Laplaud DA, Clavelou P, De Sèze J, Debouverie M, Brassat D, Pelletier J, Lebrun-Frenay C, Le Page E, Castelnovo G, Berger E, Hautecoeur P, Heinzlef O, Durelli L, Clerico M, Trojano M, Patti F, Vukusic S, Alpérovitch A, Carton H, d’Hooghe M, Hommes O, Hutchinson M, Adeleine P, Biron A, Cortinovis-Tourniaire P, Grimaud J, Hours M, Moreau T, Vukusic S, Confavreux C, Chauplannaz G, Confavreux C, Cortinovis-Tourniaire P, Grimaud J, Latombe D, Moreau T, Clanet M, Lau G, Rumbach L, Goas J, Rouhart F, Mazingue A, Roullet E, Madigand M, Hautecoeur P, Brunet P, Edan G, Allaire C, Riffault G, Leche J, Benoit T, Simonin C, Ziegler F, Baron J, Rivrain Y, Dumas R, Loche D, Bourrin J, Huttin B, Delisse B, Gibert I, Boulay C, Verceletto M, Durand G, Bonneviot G, Gil R, Hedreville M, Belair C, Poitevin R, Devoize J, Wyremblewski P, Delestre F, Setiey A, Comi G, Filippi M, Ghezzi A, Martinelli V, Rossi P, Zaffaroni M, Tola M, Amato M, Fioretti C, Meucci G, Inglese M, Mancardi G, Gambi D, Thomas A, Cavazzuti M, Citterio A, Heltberg A, Hansen H, Fernandez O, Romero F, Arbizu T, Hernandez J, De Andres de Frutos C, Geffner Sclarky D, Aladro Benito Y, Reyes Yanes P, Aguilar M, Burguera J, Yaya R, Bonakim Dib W, Arzua-Mouronte D, d’Hooghe M, Sindic C, Carton H, Medaer R, Roose H, Geens K, Guillaume D, Van Zandycke M, Janssens J, Cornette M, Mol L, Weilbach F, Flachenecker P, Hartung H, Haas J, Tendolkar I, Sindrn E, Kölmel H, Reichel D, Rauch M, Preuss S, Poser S, Mauch E, Strausser-Fuchs S, Kolleger H, Hawkins S, Howell S, Rees J, Thompson A, Johnson M, Boggild M, Gregory R, Bates D, Bone I, Hutchinson M, Polman C, Frequin S, Jongen P, Hommes O, Correia de Sa J, Rio M, Huber S, Lechner-Scott J, Kappos L, Ionescu I, Cornu C, Confavreux C, Vukusic S, El-Etr M, Baulieu E, El-Etr M, Schumacher M, Ionescu I, Confavreux C, Cornu C, Vukusic S, Hartung H, Miller D, Hutchinson M, Pugeat M, d’Archangues C, Conard J, Ménard J, Sitruk-Ware R, Pelissier C, Dat S, Belaïsch-Allard J, Athéa N, Büschsenschutz D, Lyon-Caen O, Gonsette R, Boissel J, Ffrench P, Durand-Dubief F, Cotton F, Pachai C, Bracoud L, Vukusic S, Ionescu I, Androdias G, Marignier R, Chauplannaz G, Laplaud D, Wiertlewski S, Lanctin-Garcia C, Moreau T, Couvreur G, Madinier G, Clavelou P, Taithe F, Aufauvre D, Guy N, Ferrier A, De Sèze J, Collongues N, Debouverie M, Viala F, Brassat D, Gerdelat-Mas A, Henry P, Pelletier J, Rico-Lamy A, Lebrun-Frenay C, Lepage E, Deburghraeve V, Edan G, Castelnovo G, Berger E, Hautecoeur P, Blondiau M, Heinzlef O, Coustans M, Clerc C, Rieu L, Lauxerois M, Hinzelin G, Ouallet J, Minier D, Vion P, Gromaire-Fayolle N, Derache N, Thouvenot E, Sallansonnet-Froment M, Tourniaire P, Toureille L, Borgel F, Stankoff B, Grimaud J, Moroianu C, Guennoc A, Tournier-Gervason C, Peysson S, Trojano M, Patti F, D’Amico E, Motti L, Zaffaroni M, Durelli L, Tavella A. Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. Mult Scler 2018; 25:591-600. [DOI: 10.1177/1352458518763080] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Background: Obstetrical analgesia remains a matter of controversy because of the fear of neurotoxicity of local anesthetics on demyelinated fibers or their potential relationship with subsequent relapses. Objective: To assess the impact of neuraxial analgesia on the risk of relapse during the first 3 months post-partum, with a focus on women who experienced relapses during pregnancy. Methods: We analyzed data of women followed-up prospectively during their pregnancies and at least 3 months post-partum, collected in the Pregnancy in Multiple Sclerosis (PRIMS) and Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis (POPARTMUS) studies between 1992–1995 and 2005–2012, respectively. The association of neuraxial analgesia with the occurrence of a post-partum relapse was estimated by logistic regression analysis. Results: A total of 389 women were included, 215 from PRIMS and 174 from POPARTMUS. In total, 156 women (40%) had neuraxial analgesia. Overall, 24% experienced a relapse during pregnancy and 25% in the 3 months post-partum. Women with a pregnancy relapse were more likely to have a post-partum relapse (odds ratio (OR) = 1.83, p = 0.02), independently of the use of neuraxial analgesia. There was no association between neuraxial analgesia and post-partum relapse (OR = 1.08, p = 0.78). Conclusion: Neuraxial analgesia was not associated with an increased risk of post-partum relapses, whatever multiple sclerosis (MS) activity during pregnancy.
Collapse
Affiliation(s)
- Caroline Lavie
- Service de Neurologie A, Hôpital Pierre Wertheimer,
Hospices Civils de Lyon, Lyon, France
| | - Fabien Rollot
- Observatoire Français de la Sclérose en Plaques (OFSEP),
Lyon, France
| | | | - Romain Marignier
- Service de Neurologie A, Hôpital Pierre Wertheimer,
Hospices Civils de Lyon, Lyon, France/Centre de Recherche en Neurosciences de Lyon,
INSERM U1028, CNRS UMR5292, Equipe Neuro-Oncologie et Neuro-Inflammation, Lyon, France;
Université de Lyon 1, Lyon, France
| | - Iuliana Ionescu
- Service de Neurologie A, Hôpital Pierre Wertheimer,
Hospices Civils de Lyon, Lyon, France
| | - Romain Casey
- Observatoire Français de la Sclérose en Plaques (OFSEP),
Lyon, France
| | - Thibault Moreau
- Department of Neurology, EA4184, University Hospital of
Dijon, Dijon, France
| | | | - Michael Hutchinson
- School of Medicine and Medical Science, University College
Dublin, Dublin, Ireland/Department of Neurology, St Vincent’s University Hospital,
Dublin, Ireland
| | - Marie Béatrice D’Hooghe
- National MS Center Melsbroek, Melsbroek, Belgium; Center
for Neurosciences, Vrije Universiteit Brussel (VUB), Brussel, Belgium
| | - David-Axel Laplaud
- Service de Neurologie, CHU de Nantes, CIC015 INSERM,
Nantes, France/INSERM UMR1064, Nantes, France
| | - Pierre Clavelou
- Service de Neurologie, CHU de Clermont-Ferrand,
Clermont-Ferrand, France/INSERM UMR1107, Clermont Université, Université d’Auvergne,
Neuro-Dol, Clermont-Ferrand, France
| | - Jérôme De Sèze
- Department of Neurology, Clinical Investigation Center
INSERM 1434, Hôpitaux Universitaires de Strasbourg, FMTS INSERM 1119, Strasbourg,
France
| | - Marc Debouverie
- EA 4360 APEMAC, University of Lorraine, Nancy,
France/Department of Neurology, Nancy University Hospital, Nancy, France
| | - David Brassat
- Pôle Neurosciences, CHU Toulouse Purpan, Toulouse,
France/INSERM U1043, CNRS UMR 5282, Université Toulouse III, Toulouse, France
| | - Jean Pelletier
- Service de Neurologie, Hôpital de la Timone, Pôle de
Neurosciences Cliniques, AP-HM, Aix-Marseille Université, Marseille, France/CNRS,
Aix-Marseille Université, CRMBM UMR7339, Marseille, France
| | | | - Emmanuelle Le Page
- Clinical Neuroscience Centre, CIC-P 1414 INSERM, Rennes
University Hospital, Rennes, France
| | | | - Eric Berger
- Department of Neurology, CHU Besançon, Besançon,
France
| | - Patrick Hautecoeur
- Service de Neurologie, Groupement des Hôpitaux de
l’Institut Catholique de Lille, Lille, France
| | - Olivier Heinzlef
- Department of Neurology, Hôpital CHI de
Poissy/Saint-Germain-en-Laye, Paris, France
| | - Luca Durelli
- Division of Neurology, Department of Clinical and
Biological Sciences, University of Torino, San Luigi Gonzaga University Hospital,
Orbassano, Italy
| | - Marinella Clerico
- Division of Neurology, Department of Clinical and
Biological Sciences, University of Torino, San Luigi Gonzaga University Hospital,
Orbassano, Italy
| | - Maria Trojano
- Department of Basic Medical Sciences, Neuroscience and
Sense Organs, University of Bari Aldo Moro, Bari, Italy
| | - Francesco Patti
- Department of Medical and Surgical Sciences, and Advanced
Technologies, G.F. Ingrassia, Multiple Sclerosis Center, University of Catania, Catania,
Italy
| | - Sandra Vukusic
- Service de Neurologie A, Hôpital Pierre Wertheimer,
Hospices Civils de Lyon, Lyon, France/Observatoire Français de la Sclérose en Plaques
(OFSEP), Lyon, France/Centre de Recherche en Neurosciences de Lyon, INSERM U1028, CNRS
UMR5292, Equipe Neuro-Oncologie et Neuro-Inflammation, Lyon, France/Université de Lyon
1, Lyon, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Rolla S, De Mercanti SF, Bardina V, Horakova D, Habek M, Adamec I, Cocco E, Annovazzi P, Vladic A, Novelli F, Durelli L, Clerico M. Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses. J Neuroimmunol 2017; 313:89-91. [PMID: 29153614 DOI: 10.1016/j.jneuroim.2017.10.009] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2017] [Revised: 10/04/2017] [Accepted: 10/15/2017] [Indexed: 01/01/2023]
Abstract
Alemtuzumab, a highly effective treatment for relapsing remitting multiple sclerosis (RRMS), induces lymphopenia especially of CD4+ T cells. Here, we report the atypical CD4+ T population behaviour of two patients with persistent disease activity despite repeated alemtuzumab treatments. Whereas lymphocytes count decreased and fluctuated accordingly to alemtuzumab administration, their CD4+ cell percentage was not or just mildly affected and was slightly below the lowest normal limit already before alemtuzumab. These cases anticipate further studies aimed to investigate whether the evaluation of the CD4+ cell percentage could represent a helpful tool to address the individual clinical response to alemtuzumab.
Collapse
Affiliation(s)
- Simona Rolla
- Clinical and Biological Sciences Department, University of Torino, San Luigi Gonzaga Hospital, Orbassano (TO), Italy
| | - Stefania Federica De Mercanti
- Clinical and Biological Sciences Department, University of Torino, San Luigi Gonzaga Hospital, Orbassano (TO), Italy
| | - Valentina Bardina
- Clinical and Biological Sciences Department, University of Torino, San Luigi Gonzaga Hospital, Orbassano (TO), Italy
| | - Dana Horakova
- Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University, General University Hospital, Czech Republic
| | - Mario Habek
- Department of Neurology, Referral Center for Autonomic Nervous System, University Hospital Center, University of Zagreb, School of Medicine, Zagreb, Croatia
| | - Ivan Adamec
- Department of Neurology, Referral Center for Autonomic Nervous System, University Hospital Center, University of Zagreb, School of Medicine, Zagreb, Croatia
| | - Eleonora Cocco
- Multiple Sclerosis Center, Department of Medical Science and Public Health, University of Cagliari, Italy
| | - Pietro Annovazzi
- Multiple Sclerosis Study Center, AO S. Antonio Abate, Gallarate (VA), Italy
| | - Anton Vladic
- Department of Neurology, Clinical Hospital Sveti Duh Zagreb, Medical Faculty University, J.J. Strossmayer, Osijek, Croatia
| | - Francesco Novelli
- Center for Experimental Research and Medical Studies (CERMS), Azienda Ospedaliera Città della Salute e della Scienza di Torino, Italy
| | - Luca Durelli
- Clinical and Biological Sciences Department, University of Torino, San Luigi Gonzaga Hospital, Orbassano (TO), Italy
| | - Marinella Clerico
- Clinical and Biological Sciences Department, University of Torino, San Luigi Gonzaga Hospital, Orbassano (TO), Italy.
| |
Collapse
|
5
|
Clerico M, Artusi CA, Di Liberto A, Rolla S, Bardina V, Barbero P, De Mercanti SF, Durelli L. Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis. Expert Opin Drug Saf 2017. [PMID: 28641055 DOI: 10.1080/14740338.2017.1346082] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
INTRODUCTION Natalizumab is a humanized monoclonal antibody highly effective in relapsing-remitting multiple sclerosis (MS). Important concerns about its safety have been pointed out mainly because of the risk of progressive multifocal leukoencephalopathy (PML), caused by the opportunistic John-Cunningham virus (JCV). Areas covered: This review analyzes all the safety aspects related to the use and safety of natalizumab in MS patients. Other than PML, post-marketing, safety red-flags have been reported, as liver or haematological serious adverse events. Pregnancy evidences will be pointed out. The risk of PML depends on: concomitant or previous immunosuppression, exposure duration, anti-JCV antibody level. In natalizumab-related PML the average survival is 77%; prognostic features and information for the earliest identification of PML have been identified to maximally reduce its incidence, mortality and morbidity. Expert opinion: Natalizumab is a highly effective drug for MS patients but its safety issues represent a relevant limitation and impose strict clinical surveillance of treated patients. Some post-marketing safety red-flags have been pointed out, with higher attention to severe liver failures and limphoma cases. If PML and its consequences are considered the most relevant issues, a continuous surveillance must be maintained also regarding other possible SAEs like liver diseases and malignancies.
Collapse
Affiliation(s)
- Marinella Clerico
- a Clinical and Biological Sciences Department , University of Torino , Italy
| | | | | | - Simona Rolla
- a Clinical and Biological Sciences Department , University of Torino , Italy
| | - Valentina Bardina
- a Clinical and Biological Sciences Department , University of Torino , Italy
| | - Pierangelo Barbero
- a Clinical and Biological Sciences Department , University of Torino , Italy
| | | | - Luca Durelli
- a Clinical and Biological Sciences Department , University of Torino , Italy
| |
Collapse
|
6
|
Clerico M, Artusi CA, Liberto AD, Rolla S, Bardina V, Barbero P, Mercanti SFD, Durelli L. Natalizumab in Multiple Sclerosis: Long-Term Management. Int J Mol Sci 2017; 18:ijms18050940. [PMID: 28468254 PMCID: PMC5454853 DOI: 10.3390/ijms18050940] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2017] [Revised: 04/24/2017] [Accepted: 04/26/2017] [Indexed: 12/29/2022] Open
Abstract
Natalizumab is a monoclonal antibody highly effective in the treatment of relapsing remitting multiple sclerosis (RRMS) patients. Despite its effectiveness, there are growing concerns regarding the risk of progressive multifocal leukoencephalopathy (PML), a brain infection caused by John Cunningham virus (JCV), particularly after 24 doses and in patients who previously received immunosuppressive drugs. Long-term natalizumab treated, immunosuppressive-pretreated, and JCV antibody-positive patients are asked to rediscuss natalizumab continuation or withdrawal after 24 doses. Until now, there has not been a clear strategy that should be followed to avoid PML risk and in parallel reduce clinical and radiological rebound activity. In this review, we analyzed the results of clinical trials and case reports in relation to the following situations: natalizumab continuation, natalizumab discontinuation followed by full therapeutic suspension or switch to other first or second line MS treatments. Quitting all MS treatment after natalizumab increases MS activity occurrence. The results regarding the therapeutic switch are not homogeneous, so at the moment there are no established guidelines regarding natalizumab treatment after 24 administrations; the choice is currently based on the professional experience of the neurologist, and on patients' clinical features and preferences.
Collapse
Affiliation(s)
- Marinella Clerico
- Clinical and Biological Sciences Department, University of Torino, Orbassano (TO) 10043, Italy.
| | - Carlo Alberto Artusi
- Clinical and Biological Sciences Department, University of Torino, Orbassano (TO) 10043, Italy.
| | - Alessandra Di Liberto
- Clinical and Biological Sciences Department, University of Torino, Orbassano (TO) 10043, Italy.
| | - Simona Rolla
- Clinical and Biological Sciences Department, University of Torino, Orbassano (TO) 10043, Italy.
| | - Valentina Bardina
- Clinical and Biological Sciences Department, University of Torino, Orbassano (TO) 10043, Italy.
| | - Pierangelo Barbero
- Clinical and Biological Sciences Department, University of Torino, Orbassano (TO) 10043, Italy.
| | | | - Luca Durelli
- Clinical and Biological Sciences Department, University of Torino, Orbassano (TO) 10043, Italy.
| |
Collapse
|
7
|
Clerico M, De Mercanti S, Artusi CA, Durelli L, Naismith RT. Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab. Mult Scler 2017; 23:874-876. [DOI: 10.1177/1352458516688350] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Alemtuzumab is a humanized monoclonal antibody targeting the surface molecule CD52, resulting in a rapid depletion of innate and adaptive immune cells. Infection rates in multiple sclerosis (MS) treatment trials were higher in alemtuzumab than in interferon beta–treated patients. We report two MS patients who developed cytomegalovirus disease within 1 month after the first 5-day cycle of alemtuzumab. Upon identification and appropriate treatment of the infection, each recovered completely. Neurologists should be aware of this serious but treatable complication.
Collapse
Affiliation(s)
- Marinella Clerico
- Clinical and Biological Sciences Department, Neurology Unit, University of Torino, San Luigi Gonzaga Hospital, Orbassano, Italy
| | - Stefania De Mercanti
- Clinical and Biological Sciences Department, Neurology Unit, University of Torino, San Luigi Gonzaga Hospital, Orbassano, Italy
| | - Carlo Alberto Artusi
- Clinical and Biological Sciences Department, Neurology Unit, University of Torino, San Luigi Gonzaga Hospital, Orbassano, Italy
| | - Luca Durelli
- Clinical and Biological Sciences Department, Neurology Unit, University of Torino, San Luigi Gonzaga Hospital, Orbassano, Italy
| | | |
Collapse
|
8
|
Barbero P, Busso M, Artusi CA, De Mercanti S, Tinivella M, Veltri A, Durelli L, Clerico M. Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea. J Vis Exp 2016. [PMID: 27911406 DOI: 10.3791/54606] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
Abstract
Neurological diseases can be complicated by sialorrhea, an excessive flow of saliva. Patients suffering from moderate to severe sialorrhea have an impaired quality of life, often worsened by correlated complications such as aspiration pneumonia, oral infections, dental caries, and maceration of the skin. Diverse therapeutic approaches have been proposed for the treatment of sialorrhea, including surgery and the use of anticholinergic agents, with limited results and the possible occurrence of serious adverse events. Recently, botulinum toxin (BoNT) injection within the major salivary glands has been proposed in patients refractory to anticholinergic therapy, with the aim of inhibiting local acetylcholine release and gland activity. In order to obtain a better outcome in terms of reduction of saliva production, efficacy, duration, and avoidance of major adverse events, we developed an ultrasound-guided BoNT-type A injection technique accurately described in the text. Here we present a method of treating sialorrhea with bilateral parotid and submandibular gland BoNT-type A injections under ultrasound guidance. Four quadrants of the parotid gland and two quadrants of the submandibular gland are visualized and injected using two accesses and one access, respectively. The ultrasound-guided procedure provides a simple, non-invasive, real-time visualization of the muscular and glandular tissues and their surrounding structures, optimizing treatment efficacy and safety.
Collapse
Affiliation(s)
- Pierangelo Barbero
- Clinical and Biological Sciences Department, Neurology Unit, University of Torino, San Luigi Gonzaga Hospital
| | - Marco Busso
- Oncology Department, Radiology Unit, University of Torino, San Luigi Gonzaga Hospital
| | - Carlo Alberto Artusi
- Clinical and Biological Sciences Department, Neurology Unit, University of Torino, San Luigi Gonzaga Hospital;
| | - Stefania De Mercanti
- Clinical and Biological Sciences Department, Neurology Unit, University of Torino, San Luigi Gonzaga Hospital
| | - Marco Tinivella
- Clinical and Biological Sciences Department, Dietologic and Nutrition Unit, University of Torino, San Luigi Gonzaga Hospital
| | - Andrea Veltri
- Oncology Department, Radiology Unit, University of Torino, San Luigi Gonzaga Hospital
| | - Luca Durelli
- Clinical and Biological Sciences Department, Neurology Unit, University of Torino, San Luigi Gonzaga Hospital
| | - Marinella Clerico
- Clinical and Biological Sciences Department, Neurology Unit, University of Torino, San Luigi Gonzaga Hospital
| |
Collapse
|
9
|
De Mercanti S, Rolla S, Cucci A, Bardina V, Cocco E, Vladic A, Soldo-Butkovic S, Habek M, Adamec I, Horakova D, Annovazzi P, Novelli F, Durelli L, Clerico M. Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months. Neurol Neuroimmunol Neuroinflamm 2016; 3:e194. [PMID: 26819963 PMCID: PMC4723135 DOI: 10.1212/nxi.0000000000000194] [Citation(s) in RCA: 58] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/14/2015] [Accepted: 10/30/2015] [Indexed: 01/29/2023]
Abstract
OBJECTIVE To analyze changes in T-helper (Th) subsets, T-regulatory (Treg) cell percentages and function, and mRNA levels of immunologically relevant molecules during a 24-month follow-up after alemtuzumab treatment in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS Multicenter follow-up of 29 alemtuzumab-treated patients with RRMS in the Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis (CARE-MS) I and CARE-MS II trials. Peripheral blood (PB) samples were obtained at months 0, 6, 12, 18, and 24. We evaluated (1) mRNA levels of 26 immunologic molecules (cytokines, chemokines, chemokine receptors, and transcriptional factors); (2) Th1, Th17, and Treg cell percentages; and (3) myelin basic protein (MBP)-specific Treg suppressor activity. RESULTS We observed 12 relapses in 9 patients. mRNA levels of the anti-inflammatory cytokines interleukin (IL)-10, IL-27, and transforming growth factor-β persistently increased whereas those of proinflammatory molecules related to the Th1 or Th17 subsets persistently decreased after alemtuzumab administration throughout the follow-up period. PB CD4+ cell percentage remained significantly lower than baseline while that of Th1 and Th17 cells did not significantly change. A significant increase in Treg cell percentage was observed at month 24 and was accompanied by an increase in Treg cell suppressive activity against MBP-specific Th1 and Th17 cells. CONCLUSIONS The long-lasting therapeutic benefit of alemtuzumab in RRMS may involve a shift in the cytokine balance towards inhibition of inflammation associated with a reconstitution of the PB CD4+ T-cell subsets that includes expansion of Treg cells with increased suppressive function.
Collapse
Affiliation(s)
- Stefania De Mercanti
- Division of Neurology (S.D.M., S.R., A.C., L.D., M.C.) and the Department of Clinical and Biological Sciences (S.D.M., A.C., L.D., M.C.), University of Torino, San Luigi Gonzaga University Hospital, Orbassano; Center for Experimental Research and Medical Studies (CERMS) (S.R., V.B., F.N.), Azienda Ospedaliera Città della Salute e della Scienza di Torino; Department of Molecular Biotechnology and Health Sciences (V.B., F.N.), Università degli Studi di Torino; Multiple Sclerosis Center (E.C.), Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Italy; Department of Neurology (A.V., S.S.-B.), Clinical Hospital Sveti Duh Zagreb; Medical Faculty University (A.V., S.S.-B.), J.J. Strossmayer Osijek; Department of Neurology (M.H., I.A.), Referral Center for Demyelinating Diseases of the Central Nervous System, University Hospital Center Zagreb, Croatia; Department of Neurology and Center of Clinical Neuroscience (D.H.), Charles University in Prague, First Faculty of Medicine and General University Hospital, Czech Republic; and Multiple Sclerosis Study Center (P.A.), AO S. Antonio Abate, Gallarate (VA), Italy
| | - Simona Rolla
- Division of Neurology (S.D.M., S.R., A.C., L.D., M.C.) and the Department of Clinical and Biological Sciences (S.D.M., A.C., L.D., M.C.), University of Torino, San Luigi Gonzaga University Hospital, Orbassano; Center for Experimental Research and Medical Studies (CERMS) (S.R., V.B., F.N.), Azienda Ospedaliera Città della Salute e della Scienza di Torino; Department of Molecular Biotechnology and Health Sciences (V.B., F.N.), Università degli Studi di Torino; Multiple Sclerosis Center (E.C.), Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Italy; Department of Neurology (A.V., S.S.-B.), Clinical Hospital Sveti Duh Zagreb; Medical Faculty University (A.V., S.S.-B.), J.J. Strossmayer Osijek; Department of Neurology (M.H., I.A.), Referral Center for Demyelinating Diseases of the Central Nervous System, University Hospital Center Zagreb, Croatia; Department of Neurology and Center of Clinical Neuroscience (D.H.), Charles University in Prague, First Faculty of Medicine and General University Hospital, Czech Republic; and Multiple Sclerosis Study Center (P.A.), AO S. Antonio Abate, Gallarate (VA), Italy
| | - Angele Cucci
- Division of Neurology (S.D.M., S.R., A.C., L.D., M.C.) and the Department of Clinical and Biological Sciences (S.D.M., A.C., L.D., M.C.), University of Torino, San Luigi Gonzaga University Hospital, Orbassano; Center for Experimental Research and Medical Studies (CERMS) (S.R., V.B., F.N.), Azienda Ospedaliera Città della Salute e della Scienza di Torino; Department of Molecular Biotechnology and Health Sciences (V.B., F.N.), Università degli Studi di Torino; Multiple Sclerosis Center (E.C.), Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Italy; Department of Neurology (A.V., S.S.-B.), Clinical Hospital Sveti Duh Zagreb; Medical Faculty University (A.V., S.S.-B.), J.J. Strossmayer Osijek; Department of Neurology (M.H., I.A.), Referral Center for Demyelinating Diseases of the Central Nervous System, University Hospital Center Zagreb, Croatia; Department of Neurology and Center of Clinical Neuroscience (D.H.), Charles University in Prague, First Faculty of Medicine and General University Hospital, Czech Republic; and Multiple Sclerosis Study Center (P.A.), AO S. Antonio Abate, Gallarate (VA), Italy
| | - Valentina Bardina
- Division of Neurology (S.D.M., S.R., A.C., L.D., M.C.) and the Department of Clinical and Biological Sciences (S.D.M., A.C., L.D., M.C.), University of Torino, San Luigi Gonzaga University Hospital, Orbassano; Center for Experimental Research and Medical Studies (CERMS) (S.R., V.B., F.N.), Azienda Ospedaliera Città della Salute e della Scienza di Torino; Department of Molecular Biotechnology and Health Sciences (V.B., F.N.), Università degli Studi di Torino; Multiple Sclerosis Center (E.C.), Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Italy; Department of Neurology (A.V., S.S.-B.), Clinical Hospital Sveti Duh Zagreb; Medical Faculty University (A.V., S.S.-B.), J.J. Strossmayer Osijek; Department of Neurology (M.H., I.A.), Referral Center for Demyelinating Diseases of the Central Nervous System, University Hospital Center Zagreb, Croatia; Department of Neurology and Center of Clinical Neuroscience (D.H.), Charles University in Prague, First Faculty of Medicine and General University Hospital, Czech Republic; and Multiple Sclerosis Study Center (P.A.), AO S. Antonio Abate, Gallarate (VA), Italy
| | - Eleonora Cocco
- Division of Neurology (S.D.M., S.R., A.C., L.D., M.C.) and the Department of Clinical and Biological Sciences (S.D.M., A.C., L.D., M.C.), University of Torino, San Luigi Gonzaga University Hospital, Orbassano; Center for Experimental Research and Medical Studies (CERMS) (S.R., V.B., F.N.), Azienda Ospedaliera Città della Salute e della Scienza di Torino; Department of Molecular Biotechnology and Health Sciences (V.B., F.N.), Università degli Studi di Torino; Multiple Sclerosis Center (E.C.), Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Italy; Department of Neurology (A.V., S.S.-B.), Clinical Hospital Sveti Duh Zagreb; Medical Faculty University (A.V., S.S.-B.), J.J. Strossmayer Osijek; Department of Neurology (M.H., I.A.), Referral Center for Demyelinating Diseases of the Central Nervous System, University Hospital Center Zagreb, Croatia; Department of Neurology and Center of Clinical Neuroscience (D.H.), Charles University in Prague, First Faculty of Medicine and General University Hospital, Czech Republic; and Multiple Sclerosis Study Center (P.A.), AO S. Antonio Abate, Gallarate (VA), Italy
| | - Anton Vladic
- Division of Neurology (S.D.M., S.R., A.C., L.D., M.C.) and the Department of Clinical and Biological Sciences (S.D.M., A.C., L.D., M.C.), University of Torino, San Luigi Gonzaga University Hospital, Orbassano; Center for Experimental Research and Medical Studies (CERMS) (S.R., V.B., F.N.), Azienda Ospedaliera Città della Salute e della Scienza di Torino; Department of Molecular Biotechnology and Health Sciences (V.B., F.N.), Università degli Studi di Torino; Multiple Sclerosis Center (E.C.), Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Italy; Department of Neurology (A.V., S.S.-B.), Clinical Hospital Sveti Duh Zagreb; Medical Faculty University (A.V., S.S.-B.), J.J. Strossmayer Osijek; Department of Neurology (M.H., I.A.), Referral Center for Demyelinating Diseases of the Central Nervous System, University Hospital Center Zagreb, Croatia; Department of Neurology and Center of Clinical Neuroscience (D.H.), Charles University in Prague, First Faculty of Medicine and General University Hospital, Czech Republic; and Multiple Sclerosis Study Center (P.A.), AO S. Antonio Abate, Gallarate (VA), Italy
| | - Silva Soldo-Butkovic
- Division of Neurology (S.D.M., S.R., A.C., L.D., M.C.) and the Department of Clinical and Biological Sciences (S.D.M., A.C., L.D., M.C.), University of Torino, San Luigi Gonzaga University Hospital, Orbassano; Center for Experimental Research and Medical Studies (CERMS) (S.R., V.B., F.N.), Azienda Ospedaliera Città della Salute e della Scienza di Torino; Department of Molecular Biotechnology and Health Sciences (V.B., F.N.), Università degli Studi di Torino; Multiple Sclerosis Center (E.C.), Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Italy; Department of Neurology (A.V., S.S.-B.), Clinical Hospital Sveti Duh Zagreb; Medical Faculty University (A.V., S.S.-B.), J.J. Strossmayer Osijek; Department of Neurology (M.H., I.A.), Referral Center for Demyelinating Diseases of the Central Nervous System, University Hospital Center Zagreb, Croatia; Department of Neurology and Center of Clinical Neuroscience (D.H.), Charles University in Prague, First Faculty of Medicine and General University Hospital, Czech Republic; and Multiple Sclerosis Study Center (P.A.), AO S. Antonio Abate, Gallarate (VA), Italy
| | - Mario Habek
- Division of Neurology (S.D.M., S.R., A.C., L.D., M.C.) and the Department of Clinical and Biological Sciences (S.D.M., A.C., L.D., M.C.), University of Torino, San Luigi Gonzaga University Hospital, Orbassano; Center for Experimental Research and Medical Studies (CERMS) (S.R., V.B., F.N.), Azienda Ospedaliera Città della Salute e della Scienza di Torino; Department of Molecular Biotechnology and Health Sciences (V.B., F.N.), Università degli Studi di Torino; Multiple Sclerosis Center (E.C.), Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Italy; Department of Neurology (A.V., S.S.-B.), Clinical Hospital Sveti Duh Zagreb; Medical Faculty University (A.V., S.S.-B.), J.J. Strossmayer Osijek; Department of Neurology (M.H., I.A.), Referral Center for Demyelinating Diseases of the Central Nervous System, University Hospital Center Zagreb, Croatia; Department of Neurology and Center of Clinical Neuroscience (D.H.), Charles University in Prague, First Faculty of Medicine and General University Hospital, Czech Republic; and Multiple Sclerosis Study Center (P.A.), AO S. Antonio Abate, Gallarate (VA), Italy
| | - Ivan Adamec
- Division of Neurology (S.D.M., S.R., A.C., L.D., M.C.) and the Department of Clinical and Biological Sciences (S.D.M., A.C., L.D., M.C.), University of Torino, San Luigi Gonzaga University Hospital, Orbassano; Center for Experimental Research and Medical Studies (CERMS) (S.R., V.B., F.N.), Azienda Ospedaliera Città della Salute e della Scienza di Torino; Department of Molecular Biotechnology and Health Sciences (V.B., F.N.), Università degli Studi di Torino; Multiple Sclerosis Center (E.C.), Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Italy; Department of Neurology (A.V., S.S.-B.), Clinical Hospital Sveti Duh Zagreb; Medical Faculty University (A.V., S.S.-B.), J.J. Strossmayer Osijek; Department of Neurology (M.H., I.A.), Referral Center for Demyelinating Diseases of the Central Nervous System, University Hospital Center Zagreb, Croatia; Department of Neurology and Center of Clinical Neuroscience (D.H.), Charles University in Prague, First Faculty of Medicine and General University Hospital, Czech Republic; and Multiple Sclerosis Study Center (P.A.), AO S. Antonio Abate, Gallarate (VA), Italy
| | - Dana Horakova
- Division of Neurology (S.D.M., S.R., A.C., L.D., M.C.) and the Department of Clinical and Biological Sciences (S.D.M., A.C., L.D., M.C.), University of Torino, San Luigi Gonzaga University Hospital, Orbassano; Center for Experimental Research and Medical Studies (CERMS) (S.R., V.B., F.N.), Azienda Ospedaliera Città della Salute e della Scienza di Torino; Department of Molecular Biotechnology and Health Sciences (V.B., F.N.), Università degli Studi di Torino; Multiple Sclerosis Center (E.C.), Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Italy; Department of Neurology (A.V., S.S.-B.), Clinical Hospital Sveti Duh Zagreb; Medical Faculty University (A.V., S.S.-B.), J.J. Strossmayer Osijek; Department of Neurology (M.H., I.A.), Referral Center for Demyelinating Diseases of the Central Nervous System, University Hospital Center Zagreb, Croatia; Department of Neurology and Center of Clinical Neuroscience (D.H.), Charles University in Prague, First Faculty of Medicine and General University Hospital, Czech Republic; and Multiple Sclerosis Study Center (P.A.), AO S. Antonio Abate, Gallarate (VA), Italy
| | - Pietro Annovazzi
- Division of Neurology (S.D.M., S.R., A.C., L.D., M.C.) and the Department of Clinical and Biological Sciences (S.D.M., A.C., L.D., M.C.), University of Torino, San Luigi Gonzaga University Hospital, Orbassano; Center for Experimental Research and Medical Studies (CERMS) (S.R., V.B., F.N.), Azienda Ospedaliera Città della Salute e della Scienza di Torino; Department of Molecular Biotechnology and Health Sciences (V.B., F.N.), Università degli Studi di Torino; Multiple Sclerosis Center (E.C.), Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Italy; Department of Neurology (A.V., S.S.-B.), Clinical Hospital Sveti Duh Zagreb; Medical Faculty University (A.V., S.S.-B.), J.J. Strossmayer Osijek; Department of Neurology (M.H., I.A.), Referral Center for Demyelinating Diseases of the Central Nervous System, University Hospital Center Zagreb, Croatia; Department of Neurology and Center of Clinical Neuroscience (D.H.), Charles University in Prague, First Faculty of Medicine and General University Hospital, Czech Republic; and Multiple Sclerosis Study Center (P.A.), AO S. Antonio Abate, Gallarate (VA), Italy
| | - Francesco Novelli
- Division of Neurology (S.D.M., S.R., A.C., L.D., M.C.) and the Department of Clinical and Biological Sciences (S.D.M., A.C., L.D., M.C.), University of Torino, San Luigi Gonzaga University Hospital, Orbassano; Center for Experimental Research and Medical Studies (CERMS) (S.R., V.B., F.N.), Azienda Ospedaliera Città della Salute e della Scienza di Torino; Department of Molecular Biotechnology and Health Sciences (V.B., F.N.), Università degli Studi di Torino; Multiple Sclerosis Center (E.C.), Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Italy; Department of Neurology (A.V., S.S.-B.), Clinical Hospital Sveti Duh Zagreb; Medical Faculty University (A.V., S.S.-B.), J.J. Strossmayer Osijek; Department of Neurology (M.H., I.A.), Referral Center for Demyelinating Diseases of the Central Nervous System, University Hospital Center Zagreb, Croatia; Department of Neurology and Center of Clinical Neuroscience (D.H.), Charles University in Prague, First Faculty of Medicine and General University Hospital, Czech Republic; and Multiple Sclerosis Study Center (P.A.), AO S. Antonio Abate, Gallarate (VA), Italy
| | - Luca Durelli
- Division of Neurology (S.D.M., S.R., A.C., L.D., M.C.) and the Department of Clinical and Biological Sciences (S.D.M., A.C., L.D., M.C.), University of Torino, San Luigi Gonzaga University Hospital, Orbassano; Center for Experimental Research and Medical Studies (CERMS) (S.R., V.B., F.N.), Azienda Ospedaliera Città della Salute e della Scienza di Torino; Department of Molecular Biotechnology and Health Sciences (V.B., F.N.), Università degli Studi di Torino; Multiple Sclerosis Center (E.C.), Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Italy; Department of Neurology (A.V., S.S.-B.), Clinical Hospital Sveti Duh Zagreb; Medical Faculty University (A.V., S.S.-B.), J.J. Strossmayer Osijek; Department of Neurology (M.H., I.A.), Referral Center for Demyelinating Diseases of the Central Nervous System, University Hospital Center Zagreb, Croatia; Department of Neurology and Center of Clinical Neuroscience (D.H.), Charles University in Prague, First Faculty of Medicine and General University Hospital, Czech Republic; and Multiple Sclerosis Study Center (P.A.), AO S. Antonio Abate, Gallarate (VA), Italy
| | - Marinella Clerico
- Division of Neurology (S.D.M., S.R., A.C., L.D., M.C.) and the Department of Clinical and Biological Sciences (S.D.M., A.C., L.D., M.C.), University of Torino, San Luigi Gonzaga University Hospital, Orbassano; Center for Experimental Research and Medical Studies (CERMS) (S.R., V.B., F.N.), Azienda Ospedaliera Città della Salute e della Scienza di Torino; Department of Molecular Biotechnology and Health Sciences (V.B., F.N.), Università degli Studi di Torino; Multiple Sclerosis Center (E.C.), Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Italy; Department of Neurology (A.V., S.S.-B.), Clinical Hospital Sveti Duh Zagreb; Medical Faculty University (A.V., S.S.-B.), J.J. Strossmayer Osijek; Department of Neurology (M.H., I.A.), Referral Center for Demyelinating Diseases of the Central Nervous System, University Hospital Center Zagreb, Croatia; Department of Neurology and Center of Clinical Neuroscience (D.H.), Charles University in Prague, First Faculty of Medicine and General University Hospital, Czech Republic; and Multiple Sclerosis Study Center (P.A.), AO S. Antonio Abate, Gallarate (VA), Italy
| |
Collapse
|
10
|
Barbero P, Busso M, Tinivella M, Artusi CA, De Mercanti S, Cucci A, Veltri A, Avagnina P, Calvo A, Chio’ A, Durelli L, Clerico M. Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia. J Neurol 2015; 262:2662-7. [DOI: 10.1007/s00415-015-7894-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2015] [Revised: 08/28/2015] [Accepted: 08/29/2015] [Indexed: 10/23/2022]
|
11
|
Clerico M, Schiavetti I, De Mercanti SF, Piazza F, Gned D, Brescia Morra V, Lanzillo R, Ghezzi A, Bianchi A, Salemi G, Realmuto S, Sola P, Vitetta F, Cavalla P, Paolicelli D, Trojano M, Sormani MP, Durelli L. Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study). JAMA Neurol 2014; 71:954-60. [PMID: 24977406 DOI: 10.1001/jamaneurol.2014.1200] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
IMPORTANCE The evaluation of therapeutic choices is needed after 24 doses of natalizumab in patients with multiple sclerosis (MS). OBJECTIVE To evaluate the effect of therapeutic choices on the mean annualized relapse rate and on magnetic resonance imaging MS activity after 24 doses of natalizumab in patients with relapsing-remitting MS. DESIGN, SETTING, AND PARTICIPANTS The TY-STOP study, which recruited participants between October 22, 2010, and October 22, 2012, at 8 Italian MS centers (secondary care outpatient clinics) among 124 adult patients who demonstrated no clinical or magnetic resonance imaging MS activity after 24 doses of natalizumab. INTERVENTIONS Natalizumab, no treatment, interferon beta, glatiramer acetate, or fingolimod. MAIN OUTCOMES AND MEASURES The primary end point was the mean annualized relapse rate. Statistical analyses were performed in 124 patients with complete follow-up data among 130 patients who were recruited and stratified into study groups. In the intent-to-treat group, the decision was made to continue or interrupt natalizumab after 24 doses. In the as-treated group, natalizumab continuers received natalizumab, natalizumab switchers changed to different therapies, and natalizumab quitters discontinued natalizumab during the study year. RESULTS No significant differences in demographic or baseline clinical characteristics were found among the study participants. In the intent-to-treat group (n = 124), clinical (P = .004) and radiologic (P = .02) MS activity was significantly lower in patients continuing natalizumab (n = 43) than in patients interrupting natalizumab (n = 81), with a protective effect of natalizumab continuation on both outcomes (odds ratio [OR], 0.33; 95% CI, 0.15-0.70 for clinical activity and OR, 0.35; 95% CI, 0.15-0.79 for radiologic activity). In the as-treated group (n = 124), clinical (P = .003) and radiologic (P = .03) MS activity was significantly lower in natalizumab continuers than in natalizumab switchers or quitters, confirming a protective effect of natalizumab on the risk of relapse in natalizumab continuers compared with natalizumab quitters (OR, 4.40; 95% CI, 1.72-11.23) and natalizumab switchers (OR, 3.28; 95% CI, 0.99-10.79). No disease rebound was observed in natalizumab quitters. After natalizumab discontinuation, 1 patient developed progressive multifocal leukoencephalopathy during the observation period, with complete recovery. CONCLUSIONS AND RELEVANCE This study provides class III evidence of an increased risk of MS activity resumption after natalizumab discontinuation. Therapy discontinuation after 24 doses in natalizumab-responding patients should be considered only if the risk of progressive multifocal leukoencephalopathy is high and outweighs the benefits of continuing the drug. TRIAL REGISTRATION Osservatorio Nazionale Sulla Sperimentazione Clinica dei Medicinali No. 131/2010.
Collapse
Affiliation(s)
- Marinella Clerico
- Division of Neurology, Department of Clinical and Biological Sciences, University of Turin, San Luigi Gonzaga University Hospital, Orbassano, Italy
| | - Irene Schiavetti
- Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy
| | - Stefania F De Mercanti
- Division of Neurology, Department of Clinical and Biological Sciences, University of Turin, San Luigi Gonzaga University Hospital, Orbassano, Italy
| | - Federico Piazza
- Division of Neurology, Department of Clinical and Biological Sciences, University of Turin, San Luigi Gonzaga University Hospital, Orbassano, Italy
| | - Dario Gned
- Department of Oncology, University of Turin, San Luigi Gonzaga University Hospital, Orbassano, Italy
| | - Vincenzo Brescia Morra
- Department of Neurosciences, Reproductive, and Odontostomatological Sciences, Federico II University of Naples, Naples, Italy
| | - Roberta Lanzillo
- Department of Neurosciences, Reproductive, and Odontostomatological Sciences, Federico II University of Naples, Naples, Italy
| | - Angelo Ghezzi
- Department of Neurology II, Center of Multiple Sclerosis, Azienda Ospedaliera Sant'Antonio Abate Hospital, Gallarate, Italy
| | - Anna Bianchi
- Department of Neurology II, Center of Multiple Sclerosis, Azienda Ospedaliera Sant'Antonio Abate Hospital, Gallarate, Italy
| | - Giuseppe Salemi
- Section of Neurology, Department of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, Palermo, Italy
| | - Sabrina Realmuto
- Section of Neurology, Department of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, Palermo, Italy
| | - Patrizia Sola
- Neurology Unit, Department of Neurosciences, University of Modena and Reggio Emilia, Modena, Italy
| | - Francesca Vitetta
- Neurology Unit, Department of Neurosciences, University of Modena and Reggio Emilia, Modena, Italy
| | - Paola Cavalla
- Division of Neurology and Multiple Sclerosis Center, Department of Neurosciences, University of Turin, Città della Salute e della Scienza University Hospital, Turin, Italy
| | - Damiano Paolicelli
- Department of Neuroscience and Sense Organs, University of Bari, Bari, Italy
| | - Maria Trojano
- Department of Neuroscience and Sense Organs, University of Bari, Bari, Italy
| | - Maria Pia Sormani
- Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy
| | - Luca Durelli
- Division of Neurology, Department of Clinical and Biological Sciences, University of Turin, San Luigi Gonzaga University Hospital, Orbassano, Italy
| |
Collapse
|
12
|
Rolla S, Bardina V, De Mercanti S, Quaglino P, De Palma R, Gned D, Brusa D, Durelli L, Novelli F, Clerico M. Th22 cells are expanded in multiple sclerosis and are resistant to IFN-β. J Leukoc Biol 2014; 96:1155-64. [PMID: 25097195 DOI: 10.1189/jlb.5a0813-463rr] [Citation(s) in RCA: 62] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
Abstract
Th1 and Th17 cells have been considered as effectors in mouse EAE and in the human counterpart, MS. Recently, IL-22, a Th17-related, proinflammatory cytokine, has been associated with a new Th cell subset, defined as Th22, involved in chronic inflammatory conditions, such as psoriasis; the role of IL-22 in MS has not yet been elucidated. Here, we report that similar to Th17 cells, the number of Th22 cells increased in the PB and the CSF of RR MS patients, especially during the active phases of the disease. However, as opposed to Th17 cells, the expansion of Th22 cells occurred before the active phases of the disease. Th22 cells were found to be specific for the autoantigen MBP and also expressed high levels of CCR6 and T-bet, as for Th17 cells, indicating that Th22 self-reactive cells could have CNS-homing properties and be pathogenic in active RRMS patients. Conversely to Th17 cells, Th22 cells displayed lower levels of IFNAR1 and were insensitive to IFN-β inhibition. These data suggest that expansion of Th22 cells in MS could be one of the factors that critically influence resistance to IFN-β therapy.
Collapse
MESH Headings
- Adult
- Autoantigens/immunology
- Cell Division
- Cells, Cultured
- Clone Cells/immunology
- Female
- Gene Expression Profiling
- Humans
- Interferon-beta/pharmacology
- Interferon-gamma Release Tests
- Interleukins/biosynthesis
- Interleukins/genetics
- Lymphocyte Activation
- Male
- Middle Aged
- Multiple Sclerosis, Relapsing-Remitting/blood
- Multiple Sclerosis, Relapsing-Remitting/cerebrospinal fluid
- Multiple Sclerosis, Relapsing-Remitting/immunology
- Myelin Basic Protein/immunology
- Primary Cell Culture
- Receptors, CCR6/biosynthesis
- Receptors, CCR6/genetics
- Receptors, Chemokine/biosynthesis
- Receptors, Chemokine/genetics
- Receptors, Cytokine/biosynthesis
- Receptors, Cytokine/genetics
- T-Box Domain Proteins/metabolism
- T-Cell Antigen Receptor Specificity
- T-Lymphocyte Subsets/drug effects
- T-Lymphocyte Subsets/immunology
- T-Lymphocyte Subsets/metabolism
- T-Lymphocyte Subsets/pathology
- Th17 Cells/immunology
- Transcription Factors/metabolism
- Young Adult
- Interleukin-22
Collapse
Affiliation(s)
- Simona Rolla
- Center for Experimental Research and Medical Studies, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Turin, Italy; Department of Molecular Biotechnology and Health Sciences, Turin, Italy; Department of Clinical and Biological Sciences
| | - Valentina Bardina
- Center for Experimental Research and Medical Studies, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Turin, Italy; Department of Molecular Biotechnology and Health Sciences, Turin, Italy; Department of Clinical and Biological Sciences
| | | | - Pietro Quaglino
- Department of Medical Sciences, Dermatologic Clinic, University of Turin, Italy
| | - Raffaele De Palma
- Department of Clinical and Experimental Medicine, Second University of Naples, Italy; and
| | - Dario Gned
- Radiology, San Luigi Gonzaga School of Medicine, Orbassano, Italy
| | | | | | - Francesco Novelli
- Center for Experimental Research and Medical Studies, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Turin, Italy; Department of Molecular Biotechnology and Health Sciences, Turin, Italy; Department of Clinical and Biological Sciences,
| | | |
Collapse
|
13
|
Soragni E, Miao W, Iudicello M, Jacoby D, De Mercanti S, Clerico M, Longo F, Piga A, Ku S, Campau E, Du J, Penalver P, Rai M, Madara JC, Nazor K, O'Connor M, Maximov A, Loring JF, Pandolfo M, Durelli L, Gottesfeld JM, Rusche JR. Epigenetic therapy for Friedreich ataxia. Ann Neurol 2014; 76:489-508. [PMID: 25159818 PMCID: PMC4361037 DOI: 10.1002/ana.24260] [Citation(s) in RCA: 106] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2014] [Revised: 08/19/2014] [Accepted: 08/20/2014] [Indexed: 12/12/2022]
Abstract
OBJECTIVE To investigate whether a histone deacetylase inhibitor (HDACi) would be effective in an in vitro model for the neurodegenerative disease Friedreich ataxia (FRDA) and to evaluate safety and surrogate markers of efficacy in a phase I clinical trial in patients. METHODS We used a human FRDA neuronal cell model, derived from patient induced pluripotent stem cells, to determine the efficacy of a 2-aminobenzamide HDACi (109) as a modulator of FXN gene expression and chromatin histone modifications. FRDA patients were dosed in 4 cohorts, ranging from 30mg/day to 240mg/day of the formulated drug product of HDACi 109, RG2833. Patients were monitored for adverse effects as well as for increases in FXN mRNA, frataxin protein, and chromatin modification in blood cells. RESULTS In the neuronal cell model, HDACi 109/RG2833 increases FXN mRNA levels and frataxin protein, with concomitant changes in the epigenetic state of the gene. Chromatin signatures indicate that histone H3 lysine 9 is a key residue for gene silencing through methylation and reactivation through acetylation, mediated by the HDACi. Drug treatment in FRDA patients demonstrated increased FXN mRNA and H3 lysine 9 acetylation in peripheral blood mononuclear cells. No safety issues were encountered. INTERPRETATION Drug exposure inducing epigenetic changes in neurons in vitro is comparable to the exposure required in patients to see epigenetic changes in circulating lymphoid cells and increases in gene expression. These findings provide a proof of concept for the development of an epigenetic therapy for this fatal neurological disease.
Collapse
Affiliation(s)
- Elisabetta Soragni
- Departments of Cell and Molecular Biology, Scripps Research Institute, La Jolla, CA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Cook SD, Dhib-Jalbut S, Dowling P, Durelli L, Ford C, Giovannoni G, Halper J, Harris C, Herbert J, Li D, Lincoln JA, Lisak R, Lublin FD, Lucchinetti CF, Moore W, Naismith RT, Oehninger C, Simon J, Sormani MP. Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010. Int J MS Care 2014; 14:105-14. [PMID: 24453741 DOI: 10.7224/1537-2073-14.3.105] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
It has recently been suggested that the Lublin-Reingold clinical classification of multiple sclerosis (MS) be modified to include the use of magnetic resonance imaging (MRI). An international consensus conference sponsored by the Consortium of Multiple Sclerosis Centers (CMSC) was held from March 5 to 7, 2010, to review the available evidence on the need for such modification of the Lublin-Reingold criteria and whether the addition of MRI or other biomarkers might lead to a better understanding of MS pathophysiology and disease course over time. The conference participants concluded that evidence of new MRI gadolinium-enhancing (Gd+) T1-weighted lesions and unequivocally new or enlarging T2-weighted lesions (subclinical activity, subclinical relapses) should be added to the clinical classification of MS in distinguishing relapsing inflammatory from progressive forms of the disease. The consensus was that these changes to the classification system would provide more rigorous definitions and categorization of MS course, leading to better insights as to the evolution and treatment of MS.
Collapse
Affiliation(s)
- Stuart D Cook
- University of Medicine and Dentistry of New Jersey, Newark, NJ, USA (SDC); Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ (SDJ); VA Medical Center-East Orange, East Orange, NJ, USA (PD); Department of Clinical and Biological Sciences, San Luigi Gonzaga Medical School, University of Torino, Orbassano, Italy (LD); Multiple Sclerosis Clinic, University of New Mexico Health Sciences Center, Albuquerque, NM, USA (CF); Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry, Whitechapel, London, UK (GG); Consortium of Multiple Sclerosis Centers, Hackensack, NJ, USA (J Halper); Multiple Sclerosis Clinic, Foothills Medical Centre, Calgary, Alberta, Canada (CH); MS Comprehensive Care Center, NYU Langone Medical Center, New York, NY, USA (J Herbert); MS Clinic, University of British Columbia Hospital, Vancouver, British Columbia, Canada (DL); MS Research Group, University of Texas Health, Houston, TX, USA (JAL); Comprehensive Clinical and Research MS Center, Wayne State University, Detroit, MI, USA (RL); Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York, NY, USA (FDL); Department of Neurology, Mayo Clinic, Rochester, MN, USA (CFL); Vancouver General Hospital, Vancouver, British Columbia, Canada (WM); Department of Neurology, Washington University, St. Louis, MO, USA (RTN); LACTRIMS and Institute of Neurology, Montevideo, Uruguay (CO); VA Medical Center, Portland, OR, USA (JS); and Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy (MPS)
| | - Suhayl Dhib-Jalbut
- University of Medicine and Dentistry of New Jersey, Newark, NJ, USA (SDC); Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ (SDJ); VA Medical Center-East Orange, East Orange, NJ, USA (PD); Department of Clinical and Biological Sciences, San Luigi Gonzaga Medical School, University of Torino, Orbassano, Italy (LD); Multiple Sclerosis Clinic, University of New Mexico Health Sciences Center, Albuquerque, NM, USA (CF); Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry, Whitechapel, London, UK (GG); Consortium of Multiple Sclerosis Centers, Hackensack, NJ, USA (J Halper); Multiple Sclerosis Clinic, Foothills Medical Centre, Calgary, Alberta, Canada (CH); MS Comprehensive Care Center, NYU Langone Medical Center, New York, NY, USA (J Herbert); MS Clinic, University of British Columbia Hospital, Vancouver, British Columbia, Canada (DL); MS Research Group, University of Texas Health, Houston, TX, USA (JAL); Comprehensive Clinical and Research MS Center, Wayne State University, Detroit, MI, USA (RL); Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York, NY, USA (FDL); Department of Neurology, Mayo Clinic, Rochester, MN, USA (CFL); Vancouver General Hospital, Vancouver, British Columbia, Canada (WM); Department of Neurology, Washington University, St. Louis, MO, USA (RTN); LACTRIMS and Institute of Neurology, Montevideo, Uruguay (CO); VA Medical Center, Portland, OR, USA (JS); and Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy (MPS)
| | - Peter Dowling
- University of Medicine and Dentistry of New Jersey, Newark, NJ, USA (SDC); Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ (SDJ); VA Medical Center-East Orange, East Orange, NJ, USA (PD); Department of Clinical and Biological Sciences, San Luigi Gonzaga Medical School, University of Torino, Orbassano, Italy (LD); Multiple Sclerosis Clinic, University of New Mexico Health Sciences Center, Albuquerque, NM, USA (CF); Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry, Whitechapel, London, UK (GG); Consortium of Multiple Sclerosis Centers, Hackensack, NJ, USA (J Halper); Multiple Sclerosis Clinic, Foothills Medical Centre, Calgary, Alberta, Canada (CH); MS Comprehensive Care Center, NYU Langone Medical Center, New York, NY, USA (J Herbert); MS Clinic, University of British Columbia Hospital, Vancouver, British Columbia, Canada (DL); MS Research Group, University of Texas Health, Houston, TX, USA (JAL); Comprehensive Clinical and Research MS Center, Wayne State University, Detroit, MI, USA (RL); Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York, NY, USA (FDL); Department of Neurology, Mayo Clinic, Rochester, MN, USA (CFL); Vancouver General Hospital, Vancouver, British Columbia, Canada (WM); Department of Neurology, Washington University, St. Louis, MO, USA (RTN); LACTRIMS and Institute of Neurology, Montevideo, Uruguay (CO); VA Medical Center, Portland, OR, USA (JS); and Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy (MPS)
| | - Luca Durelli
- University of Medicine and Dentistry of New Jersey, Newark, NJ, USA (SDC); Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ (SDJ); VA Medical Center-East Orange, East Orange, NJ, USA (PD); Department of Clinical and Biological Sciences, San Luigi Gonzaga Medical School, University of Torino, Orbassano, Italy (LD); Multiple Sclerosis Clinic, University of New Mexico Health Sciences Center, Albuquerque, NM, USA (CF); Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry, Whitechapel, London, UK (GG); Consortium of Multiple Sclerosis Centers, Hackensack, NJ, USA (J Halper); Multiple Sclerosis Clinic, Foothills Medical Centre, Calgary, Alberta, Canada (CH); MS Comprehensive Care Center, NYU Langone Medical Center, New York, NY, USA (J Herbert); MS Clinic, University of British Columbia Hospital, Vancouver, British Columbia, Canada (DL); MS Research Group, University of Texas Health, Houston, TX, USA (JAL); Comprehensive Clinical and Research MS Center, Wayne State University, Detroit, MI, USA (RL); Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York, NY, USA (FDL); Department of Neurology, Mayo Clinic, Rochester, MN, USA (CFL); Vancouver General Hospital, Vancouver, British Columbia, Canada (WM); Department of Neurology, Washington University, St. Louis, MO, USA (RTN); LACTRIMS and Institute of Neurology, Montevideo, Uruguay (CO); VA Medical Center, Portland, OR, USA (JS); and Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy (MPS)
| | - Corey Ford
- University of Medicine and Dentistry of New Jersey, Newark, NJ, USA (SDC); Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ (SDJ); VA Medical Center-East Orange, East Orange, NJ, USA (PD); Department of Clinical and Biological Sciences, San Luigi Gonzaga Medical School, University of Torino, Orbassano, Italy (LD); Multiple Sclerosis Clinic, University of New Mexico Health Sciences Center, Albuquerque, NM, USA (CF); Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry, Whitechapel, London, UK (GG); Consortium of Multiple Sclerosis Centers, Hackensack, NJ, USA (J Halper); Multiple Sclerosis Clinic, Foothills Medical Centre, Calgary, Alberta, Canada (CH); MS Comprehensive Care Center, NYU Langone Medical Center, New York, NY, USA (J Herbert); MS Clinic, University of British Columbia Hospital, Vancouver, British Columbia, Canada (DL); MS Research Group, University of Texas Health, Houston, TX, USA (JAL); Comprehensive Clinical and Research MS Center, Wayne State University, Detroit, MI, USA (RL); Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York, NY, USA (FDL); Department of Neurology, Mayo Clinic, Rochester, MN, USA (CFL); Vancouver General Hospital, Vancouver, British Columbia, Canada (WM); Department of Neurology, Washington University, St. Louis, MO, USA (RTN); LACTRIMS and Institute of Neurology, Montevideo, Uruguay (CO); VA Medical Center, Portland, OR, USA (JS); and Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy (MPS)
| | - Gavin Giovannoni
- University of Medicine and Dentistry of New Jersey, Newark, NJ, USA (SDC); Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ (SDJ); VA Medical Center-East Orange, East Orange, NJ, USA (PD); Department of Clinical and Biological Sciences, San Luigi Gonzaga Medical School, University of Torino, Orbassano, Italy (LD); Multiple Sclerosis Clinic, University of New Mexico Health Sciences Center, Albuquerque, NM, USA (CF); Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry, Whitechapel, London, UK (GG); Consortium of Multiple Sclerosis Centers, Hackensack, NJ, USA (J Halper); Multiple Sclerosis Clinic, Foothills Medical Centre, Calgary, Alberta, Canada (CH); MS Comprehensive Care Center, NYU Langone Medical Center, New York, NY, USA (J Herbert); MS Clinic, University of British Columbia Hospital, Vancouver, British Columbia, Canada (DL); MS Research Group, University of Texas Health, Houston, TX, USA (JAL); Comprehensive Clinical and Research MS Center, Wayne State University, Detroit, MI, USA (RL); Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York, NY, USA (FDL); Department of Neurology, Mayo Clinic, Rochester, MN, USA (CFL); Vancouver General Hospital, Vancouver, British Columbia, Canada (WM); Department of Neurology, Washington University, St. Louis, MO, USA (RTN); LACTRIMS and Institute of Neurology, Montevideo, Uruguay (CO); VA Medical Center, Portland, OR, USA (JS); and Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy (MPS)
| | - June Halper
- University of Medicine and Dentistry of New Jersey, Newark, NJ, USA (SDC); Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ (SDJ); VA Medical Center-East Orange, East Orange, NJ, USA (PD); Department of Clinical and Biological Sciences, San Luigi Gonzaga Medical School, University of Torino, Orbassano, Italy (LD); Multiple Sclerosis Clinic, University of New Mexico Health Sciences Center, Albuquerque, NM, USA (CF); Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry, Whitechapel, London, UK (GG); Consortium of Multiple Sclerosis Centers, Hackensack, NJ, USA (J Halper); Multiple Sclerosis Clinic, Foothills Medical Centre, Calgary, Alberta, Canada (CH); MS Comprehensive Care Center, NYU Langone Medical Center, New York, NY, USA (J Herbert); MS Clinic, University of British Columbia Hospital, Vancouver, British Columbia, Canada (DL); MS Research Group, University of Texas Health, Houston, TX, USA (JAL); Comprehensive Clinical and Research MS Center, Wayne State University, Detroit, MI, USA (RL); Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York, NY, USA (FDL); Department of Neurology, Mayo Clinic, Rochester, MN, USA (CFL); Vancouver General Hospital, Vancouver, British Columbia, Canada (WM); Department of Neurology, Washington University, St. Louis, MO, USA (RTN); LACTRIMS and Institute of Neurology, Montevideo, Uruguay (CO); VA Medical Center, Portland, OR, USA (JS); and Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy (MPS)
| | - Colleen Harris
- University of Medicine and Dentistry of New Jersey, Newark, NJ, USA (SDC); Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ (SDJ); VA Medical Center-East Orange, East Orange, NJ, USA (PD); Department of Clinical and Biological Sciences, San Luigi Gonzaga Medical School, University of Torino, Orbassano, Italy (LD); Multiple Sclerosis Clinic, University of New Mexico Health Sciences Center, Albuquerque, NM, USA (CF); Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry, Whitechapel, London, UK (GG); Consortium of Multiple Sclerosis Centers, Hackensack, NJ, USA (J Halper); Multiple Sclerosis Clinic, Foothills Medical Centre, Calgary, Alberta, Canada (CH); MS Comprehensive Care Center, NYU Langone Medical Center, New York, NY, USA (J Herbert); MS Clinic, University of British Columbia Hospital, Vancouver, British Columbia, Canada (DL); MS Research Group, University of Texas Health, Houston, TX, USA (JAL); Comprehensive Clinical and Research MS Center, Wayne State University, Detroit, MI, USA (RL); Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York, NY, USA (FDL); Department of Neurology, Mayo Clinic, Rochester, MN, USA (CFL); Vancouver General Hospital, Vancouver, British Columbia, Canada (WM); Department of Neurology, Washington University, St. Louis, MO, USA (RTN); LACTRIMS and Institute of Neurology, Montevideo, Uruguay (CO); VA Medical Center, Portland, OR, USA (JS); and Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy (MPS)
| | - Joseph Herbert
- University of Medicine and Dentistry of New Jersey, Newark, NJ, USA (SDC); Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ (SDJ); VA Medical Center-East Orange, East Orange, NJ, USA (PD); Department of Clinical and Biological Sciences, San Luigi Gonzaga Medical School, University of Torino, Orbassano, Italy (LD); Multiple Sclerosis Clinic, University of New Mexico Health Sciences Center, Albuquerque, NM, USA (CF); Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry, Whitechapel, London, UK (GG); Consortium of Multiple Sclerosis Centers, Hackensack, NJ, USA (J Halper); Multiple Sclerosis Clinic, Foothills Medical Centre, Calgary, Alberta, Canada (CH); MS Comprehensive Care Center, NYU Langone Medical Center, New York, NY, USA (J Herbert); MS Clinic, University of British Columbia Hospital, Vancouver, British Columbia, Canada (DL); MS Research Group, University of Texas Health, Houston, TX, USA (JAL); Comprehensive Clinical and Research MS Center, Wayne State University, Detroit, MI, USA (RL); Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York, NY, USA (FDL); Department of Neurology, Mayo Clinic, Rochester, MN, USA (CFL); Vancouver General Hospital, Vancouver, British Columbia, Canada (WM); Department of Neurology, Washington University, St. Louis, MO, USA (RTN); LACTRIMS and Institute of Neurology, Montevideo, Uruguay (CO); VA Medical Center, Portland, OR, USA (JS); and Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy (MPS)
| | - David Li
- University of Medicine and Dentistry of New Jersey, Newark, NJ, USA (SDC); Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ (SDJ); VA Medical Center-East Orange, East Orange, NJ, USA (PD); Department of Clinical and Biological Sciences, San Luigi Gonzaga Medical School, University of Torino, Orbassano, Italy (LD); Multiple Sclerosis Clinic, University of New Mexico Health Sciences Center, Albuquerque, NM, USA (CF); Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry, Whitechapel, London, UK (GG); Consortium of Multiple Sclerosis Centers, Hackensack, NJ, USA (J Halper); Multiple Sclerosis Clinic, Foothills Medical Centre, Calgary, Alberta, Canada (CH); MS Comprehensive Care Center, NYU Langone Medical Center, New York, NY, USA (J Herbert); MS Clinic, University of British Columbia Hospital, Vancouver, British Columbia, Canada (DL); MS Research Group, University of Texas Health, Houston, TX, USA (JAL); Comprehensive Clinical and Research MS Center, Wayne State University, Detroit, MI, USA (RL); Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York, NY, USA (FDL); Department of Neurology, Mayo Clinic, Rochester, MN, USA (CFL); Vancouver General Hospital, Vancouver, British Columbia, Canada (WM); Department of Neurology, Washington University, St. Louis, MO, USA (RTN); LACTRIMS and Institute of Neurology, Montevideo, Uruguay (CO); VA Medical Center, Portland, OR, USA (JS); and Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy (MPS)
| | - John A Lincoln
- University of Medicine and Dentistry of New Jersey, Newark, NJ, USA (SDC); Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ (SDJ); VA Medical Center-East Orange, East Orange, NJ, USA (PD); Department of Clinical and Biological Sciences, San Luigi Gonzaga Medical School, University of Torino, Orbassano, Italy (LD); Multiple Sclerosis Clinic, University of New Mexico Health Sciences Center, Albuquerque, NM, USA (CF); Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry, Whitechapel, London, UK (GG); Consortium of Multiple Sclerosis Centers, Hackensack, NJ, USA (J Halper); Multiple Sclerosis Clinic, Foothills Medical Centre, Calgary, Alberta, Canada (CH); MS Comprehensive Care Center, NYU Langone Medical Center, New York, NY, USA (J Herbert); MS Clinic, University of British Columbia Hospital, Vancouver, British Columbia, Canada (DL); MS Research Group, University of Texas Health, Houston, TX, USA (JAL); Comprehensive Clinical and Research MS Center, Wayne State University, Detroit, MI, USA (RL); Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York, NY, USA (FDL); Department of Neurology, Mayo Clinic, Rochester, MN, USA (CFL); Vancouver General Hospital, Vancouver, British Columbia, Canada (WM); Department of Neurology, Washington University, St. Louis, MO, USA (RTN); LACTRIMS and Institute of Neurology, Montevideo, Uruguay (CO); VA Medical Center, Portland, OR, USA (JS); and Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy (MPS)
| | - Robert Lisak
- University of Medicine and Dentistry of New Jersey, Newark, NJ, USA (SDC); Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ (SDJ); VA Medical Center-East Orange, East Orange, NJ, USA (PD); Department of Clinical and Biological Sciences, San Luigi Gonzaga Medical School, University of Torino, Orbassano, Italy (LD); Multiple Sclerosis Clinic, University of New Mexico Health Sciences Center, Albuquerque, NM, USA (CF); Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry, Whitechapel, London, UK (GG); Consortium of Multiple Sclerosis Centers, Hackensack, NJ, USA (J Halper); Multiple Sclerosis Clinic, Foothills Medical Centre, Calgary, Alberta, Canada (CH); MS Comprehensive Care Center, NYU Langone Medical Center, New York, NY, USA (J Herbert); MS Clinic, University of British Columbia Hospital, Vancouver, British Columbia, Canada (DL); MS Research Group, University of Texas Health, Houston, TX, USA (JAL); Comprehensive Clinical and Research MS Center, Wayne State University, Detroit, MI, USA (RL); Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York, NY, USA (FDL); Department of Neurology, Mayo Clinic, Rochester, MN, USA (CFL); Vancouver General Hospital, Vancouver, British Columbia, Canada (WM); Department of Neurology, Washington University, St. Louis, MO, USA (RTN); LACTRIMS and Institute of Neurology, Montevideo, Uruguay (CO); VA Medical Center, Portland, OR, USA (JS); and Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy (MPS)
| | - Fred D Lublin
- University of Medicine and Dentistry of New Jersey, Newark, NJ, USA (SDC); Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ (SDJ); VA Medical Center-East Orange, East Orange, NJ, USA (PD); Department of Clinical and Biological Sciences, San Luigi Gonzaga Medical School, University of Torino, Orbassano, Italy (LD); Multiple Sclerosis Clinic, University of New Mexico Health Sciences Center, Albuquerque, NM, USA (CF); Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry, Whitechapel, London, UK (GG); Consortium of Multiple Sclerosis Centers, Hackensack, NJ, USA (J Halper); Multiple Sclerosis Clinic, Foothills Medical Centre, Calgary, Alberta, Canada (CH); MS Comprehensive Care Center, NYU Langone Medical Center, New York, NY, USA (J Herbert); MS Clinic, University of British Columbia Hospital, Vancouver, British Columbia, Canada (DL); MS Research Group, University of Texas Health, Houston, TX, USA (JAL); Comprehensive Clinical and Research MS Center, Wayne State University, Detroit, MI, USA (RL); Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York, NY, USA (FDL); Department of Neurology, Mayo Clinic, Rochester, MN, USA (CFL); Vancouver General Hospital, Vancouver, British Columbia, Canada (WM); Department of Neurology, Washington University, St. Louis, MO, USA (RTN); LACTRIMS and Institute of Neurology, Montevideo, Uruguay (CO); VA Medical Center, Portland, OR, USA (JS); and Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy (MPS)
| | - Claudia F Lucchinetti
- University of Medicine and Dentistry of New Jersey, Newark, NJ, USA (SDC); Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ (SDJ); VA Medical Center-East Orange, East Orange, NJ, USA (PD); Department of Clinical and Biological Sciences, San Luigi Gonzaga Medical School, University of Torino, Orbassano, Italy (LD); Multiple Sclerosis Clinic, University of New Mexico Health Sciences Center, Albuquerque, NM, USA (CF); Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry, Whitechapel, London, UK (GG); Consortium of Multiple Sclerosis Centers, Hackensack, NJ, USA (J Halper); Multiple Sclerosis Clinic, Foothills Medical Centre, Calgary, Alberta, Canada (CH); MS Comprehensive Care Center, NYU Langone Medical Center, New York, NY, USA (J Herbert); MS Clinic, University of British Columbia Hospital, Vancouver, British Columbia, Canada (DL); MS Research Group, University of Texas Health, Houston, TX, USA (JAL); Comprehensive Clinical and Research MS Center, Wayne State University, Detroit, MI, USA (RL); Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York, NY, USA (FDL); Department of Neurology, Mayo Clinic, Rochester, MN, USA (CFL); Vancouver General Hospital, Vancouver, British Columbia, Canada (WM); Department of Neurology, Washington University, St. Louis, MO, USA (RTN); LACTRIMS and Institute of Neurology, Montevideo, Uruguay (CO); VA Medical Center, Portland, OR, USA (JS); and Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy (MPS)
| | - Wayne Moore
- University of Medicine and Dentistry of New Jersey, Newark, NJ, USA (SDC); Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ (SDJ); VA Medical Center-East Orange, East Orange, NJ, USA (PD); Department of Clinical and Biological Sciences, San Luigi Gonzaga Medical School, University of Torino, Orbassano, Italy (LD); Multiple Sclerosis Clinic, University of New Mexico Health Sciences Center, Albuquerque, NM, USA (CF); Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry, Whitechapel, London, UK (GG); Consortium of Multiple Sclerosis Centers, Hackensack, NJ, USA (J Halper); Multiple Sclerosis Clinic, Foothills Medical Centre, Calgary, Alberta, Canada (CH); MS Comprehensive Care Center, NYU Langone Medical Center, New York, NY, USA (J Herbert); MS Clinic, University of British Columbia Hospital, Vancouver, British Columbia, Canada (DL); MS Research Group, University of Texas Health, Houston, TX, USA (JAL); Comprehensive Clinical and Research MS Center, Wayne State University, Detroit, MI, USA (RL); Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York, NY, USA (FDL); Department of Neurology, Mayo Clinic, Rochester, MN, USA (CFL); Vancouver General Hospital, Vancouver, British Columbia, Canada (WM); Department of Neurology, Washington University, St. Louis, MO, USA (RTN); LACTRIMS and Institute of Neurology, Montevideo, Uruguay (CO); VA Medical Center, Portland, OR, USA (JS); and Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy (MPS)
| | - Robert T Naismith
- University of Medicine and Dentistry of New Jersey, Newark, NJ, USA (SDC); Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ (SDJ); VA Medical Center-East Orange, East Orange, NJ, USA (PD); Department of Clinical and Biological Sciences, San Luigi Gonzaga Medical School, University of Torino, Orbassano, Italy (LD); Multiple Sclerosis Clinic, University of New Mexico Health Sciences Center, Albuquerque, NM, USA (CF); Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry, Whitechapel, London, UK (GG); Consortium of Multiple Sclerosis Centers, Hackensack, NJ, USA (J Halper); Multiple Sclerosis Clinic, Foothills Medical Centre, Calgary, Alberta, Canada (CH); MS Comprehensive Care Center, NYU Langone Medical Center, New York, NY, USA (J Herbert); MS Clinic, University of British Columbia Hospital, Vancouver, British Columbia, Canada (DL); MS Research Group, University of Texas Health, Houston, TX, USA (JAL); Comprehensive Clinical and Research MS Center, Wayne State University, Detroit, MI, USA (RL); Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York, NY, USA (FDL); Department of Neurology, Mayo Clinic, Rochester, MN, USA (CFL); Vancouver General Hospital, Vancouver, British Columbia, Canada (WM); Department of Neurology, Washington University, St. Louis, MO, USA (RTN); LACTRIMS and Institute of Neurology, Montevideo, Uruguay (CO); VA Medical Center, Portland, OR, USA (JS); and Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy (MPS)
| | - Carlos Oehninger
- University of Medicine and Dentistry of New Jersey, Newark, NJ, USA (SDC); Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ (SDJ); VA Medical Center-East Orange, East Orange, NJ, USA (PD); Department of Clinical and Biological Sciences, San Luigi Gonzaga Medical School, University of Torino, Orbassano, Italy (LD); Multiple Sclerosis Clinic, University of New Mexico Health Sciences Center, Albuquerque, NM, USA (CF); Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry, Whitechapel, London, UK (GG); Consortium of Multiple Sclerosis Centers, Hackensack, NJ, USA (J Halper); Multiple Sclerosis Clinic, Foothills Medical Centre, Calgary, Alberta, Canada (CH); MS Comprehensive Care Center, NYU Langone Medical Center, New York, NY, USA (J Herbert); MS Clinic, University of British Columbia Hospital, Vancouver, British Columbia, Canada (DL); MS Research Group, University of Texas Health, Houston, TX, USA (JAL); Comprehensive Clinical and Research MS Center, Wayne State University, Detroit, MI, USA (RL); Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York, NY, USA (FDL); Department of Neurology, Mayo Clinic, Rochester, MN, USA (CFL); Vancouver General Hospital, Vancouver, British Columbia, Canada (WM); Department of Neurology, Washington University, St. Louis, MO, USA (RTN); LACTRIMS and Institute of Neurology, Montevideo, Uruguay (CO); VA Medical Center, Portland, OR, USA (JS); and Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy (MPS)
| | - Jack Simon
- University of Medicine and Dentistry of New Jersey, Newark, NJ, USA (SDC); Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ (SDJ); VA Medical Center-East Orange, East Orange, NJ, USA (PD); Department of Clinical and Biological Sciences, San Luigi Gonzaga Medical School, University of Torino, Orbassano, Italy (LD); Multiple Sclerosis Clinic, University of New Mexico Health Sciences Center, Albuquerque, NM, USA (CF); Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry, Whitechapel, London, UK (GG); Consortium of Multiple Sclerosis Centers, Hackensack, NJ, USA (J Halper); Multiple Sclerosis Clinic, Foothills Medical Centre, Calgary, Alberta, Canada (CH); MS Comprehensive Care Center, NYU Langone Medical Center, New York, NY, USA (J Herbert); MS Clinic, University of British Columbia Hospital, Vancouver, British Columbia, Canada (DL); MS Research Group, University of Texas Health, Houston, TX, USA (JAL); Comprehensive Clinical and Research MS Center, Wayne State University, Detroit, MI, USA (RL); Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York, NY, USA (FDL); Department of Neurology, Mayo Clinic, Rochester, MN, USA (CFL); Vancouver General Hospital, Vancouver, British Columbia, Canada (WM); Department of Neurology, Washington University, St. Louis, MO, USA (RTN); LACTRIMS and Institute of Neurology, Montevideo, Uruguay (CO); VA Medical Center, Portland, OR, USA (JS); and Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy (MPS)
| | - Maria Pia Sormani
- University of Medicine and Dentistry of New Jersey, Newark, NJ, USA (SDC); Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ (SDJ); VA Medical Center-East Orange, East Orange, NJ, USA (PD); Department of Clinical and Biological Sciences, San Luigi Gonzaga Medical School, University of Torino, Orbassano, Italy (LD); Multiple Sclerosis Clinic, University of New Mexico Health Sciences Center, Albuquerque, NM, USA (CF); Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry, Whitechapel, London, UK (GG); Consortium of Multiple Sclerosis Centers, Hackensack, NJ, USA (J Halper); Multiple Sclerosis Clinic, Foothills Medical Centre, Calgary, Alberta, Canada (CH); MS Comprehensive Care Center, NYU Langone Medical Center, New York, NY, USA (J Herbert); MS Clinic, University of British Columbia Hospital, Vancouver, British Columbia, Canada (DL); MS Research Group, University of Texas Health, Houston, TX, USA (JAL); Comprehensive Clinical and Research MS Center, Wayne State University, Detroit, MI, USA (RL); Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York, NY, USA (FDL); Department of Neurology, Mayo Clinic, Rochester, MN, USA (CFL); Vancouver General Hospital, Vancouver, British Columbia, Canada (WM); Department of Neurology, Washington University, St. Louis, MO, USA (RTN); LACTRIMS and Institute of Neurology, Montevideo, Uruguay (CO); VA Medical Center, Portland, OR, USA (JS); and Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy (MPS)
| |
Collapse
|
15
|
De Mercanti S, Cucci A, Viglietta E, Giai Via A, Taverna D, Cimino D, Rolla S, Bardina V, Novelli F, Vargas J, Gibbin M, Piazza F, Vladic A, Brinar V, Habek M, Cocco E, Annovazzi P, Horakova D, Kovarova I, Clerico M, Durelli L. T Regulatories (Tregs) and Suppressor Cytokine mRNA (IL-10, TGF , IL-27) Increase after Alemtuzumab in MS: First 24 Month Immunological Report on 323 and 324 Genzyme Trials (P02.088). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.p02.088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
16
|
Conti L, De Palma R, Rolla S, Boselli D, Rodolico G, Kaur S, Silvennoinen O, Niccolai E, Amedei A, Ivaldi F, Clerico M, Contessa G, Uccelli A, Durelli L, Novelli F. Th17 cells in multiple sclerosis express higher levels of JAK2, which increases their surface expression of IFN-γR2. J Immunol 2012; 188:1011-8. [PMID: 22219326 DOI: 10.4049/jimmunol.1004013] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/16/2023]
Abstract
IFN-β inhibits the expansion of Th17 cells in active multiple sclerosis (AMS), and this might contribute to improve the clinical symptoms. The effectiveness of this inhibition, however, requires intact IFN-γ signaling in T cells. In this study, we report that both mRNA and cell surface expression of the signaling chain of the IFN-γ receptor (IFN-γR2) and its cognate tyrosine kinase JAK2 are enhanced in peripheral blood Th17 cells and clones from patients with AMS compared with those with inactive multiple sclerosis (IMS) or healthy subjects (HS). IFN-γ decreased the frequency of Th17 peripheral cells and proliferation of Th17 clones from AMS patients. Stimulation of PBMCs from HS in Th17-polarizing conditions resulted in the enhancement of JAK2 expression and accumulation of cell surface IFN-γR2. The role of JAK2 in the modulation of IFN-γR2 was demonstrated as its transduction prevented rapid internalization and degradation of IFN-γR2 in JAK2-deficient γ2A cells. In conclusion, these data identify JAK2 as a critical factor that stabilizes IFN-γR2 surface expression in Th17 cells from AMS patients, making them sensitive to IFN-γ. These data may have clinical implications for a better use of IFNs in multiple sclerosis and possibly other inflammatory diseases.
Collapse
Affiliation(s)
- Laura Conti
- Center for Experimental Research and Medical Studies, San Giovanni Battista Hospital, 10126 Turin, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Novelli F, De Palma R, Rolla S, Conti L, Clerico M, Cintessa G, Silveinnonen O, Durelli L. JAK2 is overexpressed in human multiple sclerosis Th17 cells and stabilizes cell surface expression of IFN-γR2 (114.14). The Journal of Immunology 2011. [DOI: 10.4049/jimmunol.186.supp.114.14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
IFN-β inhibits the expansion of T helper 17 (Th17) cells in active multiple sclerosis (AMS), and this might contribute to improve the clinical symptoms. The effectiveness of this inhibition, however, requires intact IFN-γ signaling in T cells. Here we report that both mRNA and cell surface expression of the signaling chain of the IFN-γ receptor (IFN-γR2) and its cognate tyrosine kinase JAK2 are enhanced in peripheral blood Th17 cells from patients with AMS compared with those with inactive MS (IMS) or healthy subjects (HS). Anti-CD3 mAb stimulation and IFN-γ decreased the frequency of Th17 cells in peripheral blood mononuclear cells (PBMC) from AMS patients. Stimulation of PBMC from HS in Th17-polarizing conditions resulted in enhancement of JAK2 expression and accumulation of cell surface IFN-γR2. The role of JAK2 in the modulation of IFN-γR2 was demonstrated as its transduction prevented rapid internalization and degradation of IFN-γR2 in JAK2-deficient γ2A cells. In conclusion, these data identify JAK2 as a critical factor that stabilizes IFN-γR2 surface expression in Th17 cells from AMS patients, making them sensitive to IFN-γ. These data may have clinical implications for a better use of IFNs in MS and possibly other inflammatory diseases.
Collapse
Affiliation(s)
| | | | - Simona Rolla
- 1Medicine & Experimetal Oncology, University of Turin, Turin, Italy
| | - Laura Conti
- 1Medicine & Experimetal Oncology, University of Turin, Turin, Italy
| | | | - Giulia Cintessa
- 1Medicine & Experimetal Oncology, University of Turin, Turin, Italy
| | | | - Luca Durelli
- 1Medicine & Experimetal Oncology, University of Turin, Turin, Italy
| |
Collapse
|
18
|
Rolla S, Bardina V, Clerico M, Durelli L, Novelli F. SS1-6 T helper 22 cells increase in multiple sclerosis patients: Phenotypical and functional characterization. Cytokine 2010. [DOI: 10.1016/j.cyto.2010.07.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
19
|
Novelli F, Conti L, Boselli D, Rolla S, Clerico M, Contessa G, Durelli L. Th17 lymphocytes are expanded in multiple sclerosis and are inhibited by interferons. Cytokine 2009. [DOI: 10.1016/j.cyto.2009.07.276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
20
|
Durelli L, Rolla S, Conti L, Clerico M, Contessa G, Ripellino P, La Puma D, Viglietta E, Uccelli A, Zaffaroni M, Cavalla P, Rinaldi L, Comi C, Novelli F. FP17-TU-06 Th17, an effector T lymphocyte subset associated with multiple sclerosis (MS) relapses: antigen specificity, cytokine production, and sensitivity to interferon (IFN)-β. J Neurol Sci 2009. [DOI: 10.1016/s0022-510x(09)70355-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
21
|
Durelli L, Conti L, Clerico M, Boselli D, Contessa G, Ripellino P, Ferrero B, Eid P, Novelli F. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-β. Ann Neurol 2009; 65:499-509. [DOI: 10.1002/ana.21652] [Citation(s) in RCA: 292] [Impact Index Per Article: 19.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
22
|
Citterio A, Beghi E, Millul A, Evoli A, Mantegazza R, Antozzi C, Baggi F, Cornelio F, Durelli L, Clerico M, Piccolo G, Cosi V. Risk factors for tumor occurrence in patients with myasthenia gravis. J Neurol 2009; 256:1221-7. [DOI: 10.1007/s00415-009-5091-9] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2008] [Revised: 02/09/2009] [Accepted: 02/25/2009] [Indexed: 11/30/2022]
|
23
|
Durelli L, Barbero P, Cucci A, Ferrero B, Ricci A, Contessa G, De Mercanti S, Ripellino P, Lapuma D, Viglietta E, Bergui M, Versino E, Clerico M. Neutralizing antibodies in multiple sclerosis patients treated with 375 μg interferon-β-1b. Expert Opin Biol Ther 2009; 9:387-97. [DOI: 10.1517/14712590902762781] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/09/2022]
|
24
|
Durelli L, Barbero P, Bergui M, Versino E, Bassano MA, Verdun E, Rivoiro C, Ferrero C, Picco E, Ripellino P, Giuliani G, Montanari E, Clerico M. MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008; 79:646-51. [PMID: 17986500 DOI: 10.1136/jnnp.2007.130229] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
OBJECTIVE To prospectively validate MRI activity and neutralising anti-interferon antibody (NAb) during the first 6 months of interferon beta treatment as response indicators in multiple sclerosis (MS). METHODS Patients with relapsing-remitting MS were followed during the first 2 years of treatment. Neurological assessments were performed every 3 months or when a relapse was suspected. MRI scans performed at baseline and at 3, 4, 5 and 6 months after the start of treatment were assessed centrally for disease activity: new T2 or gadolinium enhancing T1 lesions. NAb were assessed using the MxA protein assay; positivity was defined as two consecutive titres >or=20 NU/ml. We evaluated the predictivity of an active scan, NAb positivity, or both, during the first 6 months of treatment, on the occurrence of clinical disease activity in the following 18 months. RESULTS 147 patients were assessed at 16 centres. Predictivity parameters (with confidence intervals) were as follows: active scan, sensitivity (SN) 52% (34-69%), specificity (SP) 80% (65-91%), negative predictive value (NPV) 73% (58-77%), positive predictive value (PPV) 62% (42-79%), p = 0.002; NAb positivity, SN 71% (45-88%), SP 66% (55-76%), NPV 92% (82-97%), PPV 29% (16-45%), p = 0.01; active scan and NAb positivity, SN 71% (38-91%), SP 86% (73-94%), NPV 94% (86-98%), PPV 50% (29-70%), p = 0.0003. CONCLUSIONS MRI activity and NAb occurrence during the first 6 months of interferon beta treatment were reliable predictors of long term clinical response, particularly when combined. Patients with negative predictors showed a less than 10% risk of developing clinical activity. Patients with positive predictors showed a 50% risk of further clinical activity. These patients need to be followed carefully with further MRI and NAb tests.
Collapse
Affiliation(s)
- L Durelli
- Dipartimento di Scienze Cliniche e Biologiche, Universita' di Torino, Ospedale San Luigi Gonzaga, Regione Gonzole, 10, I-10043 Orbassano, Torino, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Clerico M, Faggiano F, Palace J, Rice G, Tintorè M, Durelli L. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Cochrane Database Syst Rev 2008:CD005278. [PMID: 18425915 DOI: 10.1002/14651858.cd005278.pub3] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND Immunomodulatory drugs have been shown to be only modestly effective in clinically definite relapsing remitting multiple sclerosis (RRMS). It has been hypothesized that their efficacy could be higher if used at the first appearance of symptoms, that is in the clinically isolated syndromes (CIS) suggestive of demyelinating events, a pathology which carries a high risk to convert to clinically definite MS (CDMS). OBJECTIVES The objective of this review was to assess the effects of immunomodulatory drugs compared to placebo in adults in preventing conversion from CIS to CDMS which means the prevention of a second attack. SEARCH STRATEGY We searched the Cochrane MS Group Trials Register (June 2007), Cochrane Central Register of Controlled Trials (CENTRAL)The Cochrane Library Issue 3, 2007, MEDLINE (January 1966 to June 2007), EMBASE (January 1974 to June 2007) and reference lists of articles. We also contacted manufacturers and researchers in the field. SELECTION CRITERIA The trials selected were double-blind, placebo-controlled, randomised trials of CIS patients treated with immunomodulatory drugs. DATA COLLECTION AND ANALYSIS Study selection have been independently done by two reviewers. Two further reviewers independently assessed trial quality and extracted and analysed data. Study authors were contacted for additional informations. Adverse effects information was collected from the trials. MAIN RESULTS Only three trials tested the efficacy of interferon (IFN) beta including a total of 1160 participants (639 treatment, 521 placebo); no trial tested the efficacy of glatiramer acetate (GA). The metanalyses showed that the proportion of patients converting to CDMS was significantly lower in IFN beta-treated than in placebo-treated patients both after one year (pooled OR 0.53; 95% CI, 0.40 to 0.71; p <0.0001) as well as after two years of follow-up (pooled OR 0.52; 95% CI, 0.38 to 0.70; p <0.0001). Early treatment with IFN beta was associated with the side effect profile reported by the randomised controlled trials with this drug. Since side effects were reported with some heterogeneity in the three studies the metanalysis was possible only for the frequency of serious adverse events, not significantly different in IFN beta-treated or placebo-treated patients. AUTHORS' CONCLUSIONS The efficacy of IFN beta treatment on preventing the conversion from CIS to CDMS was confirmed over two years of follow-up. Since patients had some clinical heterogeneity (length of follow-up, clinical findings of initial attack), it could be useful for the clinical practice to further analyse the efficacy of IFN beta treatment in different patient subgroups.
Collapse
Affiliation(s)
- M Clerico
- Univeristà di Torino - Ospedale S. Luigi Gonzaga, Dip.to di Neuroscienze, Regione Gonzole, 10, Orbassano, Torino, Italy, 10043.
| | | | | | | | | | | |
Collapse
|
26
|
Clerico M, Rivoiro C, Contessa G, Viglietti D, Durelli L. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews. Clin Neurol Neurosurg 2008; 110:878-85. [PMID: 18164542 DOI: 10.1016/j.clineuro.2007.10.020] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2007] [Accepted: 10/30/2007] [Indexed: 11/26/2022]
Abstract
Today many different drugs are available for treatment of multiple sclerosis (MS). Interferons, glatiramer acetate, mitoxantrone, and natalizumab have been approved by the regulatory authorities of many countries for the treatment of MS. Evidence based medicine (EBM) principles allow physicians to better address the correct treatment for patients. This article aimed to review all the clinical trials on immune-modulating and immunosuppressive drugs on the basis of the EBM principles. Based on the evidence to date interferon beta represents the best therapeutic option, particularly if given at high doses and with multiple injections per week. Due to its lower efficacy, glatiramer acetate should be used as a second choice in case of intolerable side effects or toxicity of interferon beta. Great efficacy has been demonstrated for mitoxantrone and natalizumab. These drugs should be, however, used with particular attention for their potential toxic effects.
Collapse
Affiliation(s)
- Marinella Clerico
- Dipartimento di Scienze Cliniche e Biologiche, Divisione di Neurologia, Ospedale Universitario, S.Luigi Gonzaga, Universita' di Torino, Torino, Italy
| | | | | | | | | |
Collapse
|
27
|
Novelli F, Conti L, Clerico M, Contessa G, Durelli L. Type I IFN inhibits the expansion of Th17 lymphocytes from both healthy subjects and Multiple Sclerosis patients. FASEB J 2008. [DOI: 10.1096/fasebj.22.1_supplement.1069.6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | - Laura Conti
- Medicine and Experimental OncologyUniversity of TurinTorinoItaly
| | - Marinella Clerico
- Dept of NeurologySan Luigi Gonzaga HospitalUniversity of TurinOrbassanoItaly
| | - Giulia Contessa
- Dept of NeurologySan Luigi Gonzaga HospitalUniversity of TurinOrbassanoItaly
| | - Luca Durelli
- Dept of NeurologySan Luigi Gonzaga HospitalUniversity of TurinOrbassanoItaly
| |
Collapse
|
28
|
Clerico M, Barbero P, Contessa G, Ferrero C, Durelli L. Adherence to interferon-beta treatment and results of therapy switching. J Neurol Sci 2007; 259:104-8. [PMID: 17376486 DOI: 10.1016/j.jns.2006.05.075] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2005] [Revised: 05/12/2006] [Accepted: 05/23/2006] [Indexed: 10/23/2022]
Abstract
Adherence to long-term therapy has always been a problem in all fields of medicine. In multiple sclerosis (MS), treatment consists of parenteral administration of immune-modulating drugs once or several times weekly for an as yet undetermined length of time. Different studies on the MS patients' compliance showed that the most frequent cause of stopping treatment is the perceived lack of efficacy and that most treatment withdrawals occur during the first year of treatment. A trial aimed to identify the minimum effective IFNbeta dose showed that some patients had disease activity after switching to a lower IFNbeta dose. OPTIMS (OPTimization of Interferon dose for MS study) was a multicenter study, involving 24 Italian MS centers, 216 patients, aimed to identify a treatment response indicator allowing the early identification of poorly responding patients. A single active scan during the first 6 months of IFN treatment had a significant positive predictability of 59% (95% confidence interval, 41-76; p=0.05) on the presence of clinical signs of disease activity during the further 2-year follow-up.
Collapse
Affiliation(s)
- Marinella Clerico
- Divisione Universitaria di Neurologia, Ospedale Clinicizzato San Luigi Gonzaga, Dipartimento di Scienze Cliniche e Biologiche, Universita' di Torino, Torino, Italy.
| | | | | | | | | |
Collapse
|
29
|
Abstract
At present, two types of recombinant human interferon (IFN)-beta are in clinical use. IFN-beta1a is produced in genetically engineered Chinese hamster ovary cells, and its amino acid sequence and glycosylation pattern are identical to those of endogenous human IFN-beta. The beneficial effect of IFN-beta in multiple sclerosis (MS) probably results from different mechanisms of action, such as a direct effect on plasma cells modulating IgG synthesis, an increase of interleukin (IL)-10 levels, the inhibition of IL-1beta and tumour necrosis factor alpha, the stimulation of IL-1 receptor antagonist production, the inhibition of proliferation of leukocytes, a decreased antigen presentation in microglia, a reduction of T cell migration into the brain by inhibition of the activity of T cell matrix metalloproteinases, and a downregulation of adhesion molecules. IFN-beta1a has been shown by several multicenter controlled trials to be effective in relapsing-remitting MS. It reduces relapse rate by 30-50%, magnetic resonance imaging signs of disease activity in 30-80% and disability progression by 30%. It is also effective in preventing conversion to clinically definite MS when given at the time of a first demyelinating event (i.e., at the very beginning of the clinical disease). No clear evidence of the persistence of the efficacy over the long-term has stood out from a systematic analysis of published trials. A Cochrane review concluded that, in fact, the clinical effect beyond the first year of treatment is not clear. Finally, no efficacy has been shown in secondary progressive or primary progressive MS. However, IFN-beta1a is very well tolerated and the most frequent side effects are mild (local skin reaction and flu-like symptoms) and decline in frequency or disappear after the first 3-6 months of treatment. Although the optimal frequency between once weekly or multiple weekly administrations is still controversial, all protocols require multiple monthly injections. Some patients might find it hard to cope with such a treatment regimen over the long term. Ongoing trials with new powerful immunomodulatory drugs, such as monoclonal antibodies, that require only monthly or bimonthly parenteral administrations will probably offer a better tolerated treatment option in the near future.
Collapse
Affiliation(s)
- Marinella Clerico
- Divisione Universitaria di Neurologia, Ospedale Clinicizzato San Luigi Gonzaga, Dipartimento di Scienze Cliniche e Biologiche, Università di Torino, Regione Gonzole 10, I-10043 Orbassano, TO, Italy.
| | | | | |
Collapse
|
30
|
Durelli L, Barbero P, Clerico M. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology 2007; 67:2264; author reply 2264-5. [PMID: 17190964 DOI: 10.1212/01.wnl.0000252724.67789.1e] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
31
|
Milano E, Coletti Moja M, Celotto F, Favarato C, Mauro A, Durelli L. P01.8 Remote effects of botulinum toxin therapy in hyperhydrosis treatment. Clin Neurophysiol 2006. [DOI: 10.1016/j.clinph.2006.06.185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
32
|
Barbero P, Bergui M, Versino E, Ricci A, Zhong JJ, Ferrero B, Clerico M, Pipieri A, Verdun E, Giordano L, Durelli L. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab. Mult Scler 2006; 12:72-6. [PMID: 16459722 DOI: 10.1191/135248506ms1247oa] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
BACKGROUND In RRMS, clinical exacerbations are usually associated with different types of active lesions at MRI, including: hyperintense lesions on T1-weighted post-gadolinium sequences; new hyperintense lesions or enlarging old lesions on PD/T2-weighted scans; or new hypointense lesions on T1-weighted pre-Gd sequences. OBJECTIVE/METHODS Primary outcome was the occurrence of patients with at least one active MRI lesion of the different types indicated above during treatment with 250 microg every other day (EOD) interferon beta (IFNbeta)-1b or 30 microg once weekly (OW) IFNbeta-1a in outpatients with RRMS (INCOMIN Trial). RESULTS The number of patients with at least one 'active' lesion, evaluated over the two-year follow-up, was significantly (P = 0.014) lower in the EOD IFNbeta-1 b arm (1 3/76, 17%) then in the OW IFNbeta-1a arm (25/73, 34%). NAb frequency over two-year follow-up was 22/65 (33.8%) in the EOD IFNbeta-1b arm and 4/62 (6.5%) in the OW IFNbeta-1a arm, significantly greater in the EOD IFNbeta-1b arm. CONCLUSIONS The development of MRI active lesions is strongly reduced by EOD-IFNbeta-1b compared with OW-IFNbeta-1a, indicating that EOD-IFNbeta-1b is more effective than OW-IFNbeta-1a in reducing ongoing inflammation and demyelination in MS. Logistic regression showed that NAb status did not affect the risk of MRI activity.
Collapse
Affiliation(s)
- P Barbero
- Clinica Neurologica I, Dipartimento di Neuroscienze, Università degli Studi di Torino, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Abstract
The INCOMIN study (INdependent COMparison of INterferons) lends further support to the growing body of evidence that both dose and frequency of interferon beta (IFNbeta) administration are important in the treatment of multiple sclerosis (MS). High-dose, high-frequency IFNbeta (IFNbeta-1b 250 microg eod sc and IFNbeta-1a 44 microg sc) treatment offers greater therapeutic benefit, in terms of clinical and magnetic resonance imaging (MRI) outcome measures, compared with low-dose, once-weekly administration of IFNbeta. The importance of maintaining the most effective treatment regimen has been shown in another study. The data from this study suggested that patients who have 'stable' disease (i. e. no evidence of clinical or MRI disease activity) during long-term treatment with IFNbeta-1b 250 microg, who are subsequently treated with low-dose, once-weekly IFNbeta-1a 30 microg, are more likely to experience relapses, disease progression or MRI activity compared with those remaining on IFNbeta-1b 250 microg. These data clearly indicate that frequently administered therapy must be maintained to achieve the optimal therapeutic benefit for patients. Those patients who had their IFNbeta-1b 250 microg therapy reduced to low-dose, once-weekly IFNbeta-1a and experienced a resumption of disease activity were returned to their previous regimen. However, after 1 year of additional follow-up, many of these patients still had clinical or MRI signs of disease activity, highlighting further the risks associated with the reduction of IFNbeta dose and frequency of administration. Taking into consideration the evidence supporting the greater efficacy of IFNbeta-1b 250 microg or IFNbeta-1a 44 microg in MS it is of considerable interest to examine whether it is useful to increase the dose of IFNbeta-1b in patients who do not respond satisfactorily to the approved standard dose. This is the rationale for the recently completed OPTIMS (OPTimization of Interferon for MS) study, in which partially responding patients were randomised to IFNbeta-1b 250 or 375 microg every other day. An interim safety analysis of OPTIMS patients has not raised any safety or tolerability concerns. In summary, there is consistent evidence to support the importance of maintaining frequently administered IFNbeta (IFNbeta-1b 250 microg or IFNbeta-1a 44 microg) for the treatment of MS.
Collapse
Affiliation(s)
- Luca Durelli
- University Division of Neurology, San Luigi Gonzaga University Hospital, Regione Gonzole, 10, 10043 Orbassano (Torino), Italy.
| | | |
Collapse
|
34
|
Durelli L, Clerico M. Comparison of immunomodulatory treatments for multiple sclerosis. Eur J Neurol 2005; 12:915; author reply 916. [PMID: 16241984 DOI: 10.1111/j.1468-1331.2005.01372.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
35
|
Clerico M, Faggiano F, Palace J, Rice G, Tintorè M, Durelli L. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Hippokratia 2005. [DOI: 10.1002/14651858.cd005278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
36
|
Isoardo G, Deaglio S, Cocito D, Migliaretti G, Ferrero E, Cavallo F, Durelli L, Malavasi F. Immunodetection of anti-MAG IgM antibody by cross-reactivity to LA-N-1 neuroblastoma cells. J Neuroimmunol 2005; 161:78-86. [PMID: 15748946 DOI: 10.1016/j.jneuroim.2004.12.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2004] [Revised: 12/16/2004] [Accepted: 12/17/2004] [Indexed: 10/25/2022]
Abstract
Demyelinating polyneuropathiy associated with IgM paraproteinemia and high titers of anti-MAG IgM antibodies (MAG-PN) is considered different from chronic inflammatory demyelinating polyneuropathy, particularly because of the poorer response to treatment of MAG-PN patients. Therefore, anti-MAG anitbodies may have relevant prognostic value. Available anti-MAG antibody assays require central nervous system myelin proteins from autopsied human brains. This study investigated the feasibility of detecting anti-MAG antibody by immunofluorescence and flow cytometry using a panel of human neuroblastoma cell lines as targets. We report here on the evaluation of the LA-N-1 cell line as an appropriate substrate for the detection of anti-MAG antibody by indirect immunoflourescence.
Collapse
|
37
|
Durelli L. Is multiple sclerosis a disease that requires frequent beta interferon dosing? J Neurol 2005; 251 Suppl 4:IV13-24. [PMID: 15378303 DOI: 10.1007/s00415-004-1404-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
The three currently available beta interferon products for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS) are administered according to different regimens. Placebo-controlled clinical trials support the efficacy of both alternate-day interferon beta-1b (Betaferon) and once-a-week interferon beta-1a (Avonex), but benefits to patients are probably dependent on the regimen used. Once-weekly administration, perceived to have fewer adverse events and greater convenience, may improve compliance, whereas frequent administration might enhance efficacy. However, more frequent administration is also associated with an increase in neutralising antibody (NAb) production, relative to once weekly treatment. The issue of NAbs is complex, and their clinical relevance, if any, has yet to be fully assessed. Pharmacological evidence suggests that the effects of beta interferon on a number of biological markers is maximised when administered every 48 hours. This might arise as a result of sustained activity in the intracellular molecular signalling pathways regulating beta interferon-induced gene expression. Some evidence suggests that the increase in biological effect at higher more frequent doses is mirrored by improvements in clinical and MRI outcome measures. Two recent comparative studies demonstrated significantly better clinical and magnetic resonance imaging outcomes in patients with RRMS receiving alternate-day high-dose interferon beta-1b (250 micro g subcutaneously) or three-times-weekly high-dose interferon beta-1a compared to those receiving once weekly low-dose interferon beta-1a (30 micro g intramuscularly). Despite some methodological drawbacks, these studies indicate that the benefits of high-dose frequently administered beta interferon on relapse rate are seen soon after beginning treatment. Therefore, it seems appropriate to begin the treatment of RRMS with this dosing regimen.
Collapse
Affiliation(s)
- Luca Durelli
- Department of Neuroscience, University of Turin, 10126, Turin, Italy.
| |
Collapse
|
38
|
Barbero P, Verdun E, Bergui M, Pipieri A, Clerico M, Cucci A, Ricci A, Bergamasco B, Durelli L. High-dose, frequently administered interferon beta therapy for relapsing–remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study. J Neurol Sci 2004; 222:13-9. [PMID: 15240190 DOI: 10.1016/j.jns.2004.03.023] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2003] [Revised: 03/19/2004] [Accepted: 03/20/2004] [Indexed: 01/08/2023]
Abstract
Long-term trials have demonstrated the continued efficacy of interferon (IFN) beta treatment in patients with relapsing-remitting (RR) multiple sclerosis (MS) during prolonged administration. The objective of the work was to evaluate the effects of reducing IFN beta administration frequency and total weekly dose in patients with RR MS who have achieved clinical and MRI disease activity stabilization during long-term IFN beta-1b treatment. Prospective 1-year follow-up of 27 RR MS patients on long-term 250 microg every other day (standard dose) IFN beta-1b treatment were randomized either to gradually reduce dose to 30 microg once-a-week IFN beta-1a (13 patients), or to continue on IFN beta-1b standard dose (14 patients). We found significant differences in the two group of patients. In the group of patients continuously treated with IFN beta-1b standard dose, 79% remained relapse free compared to 23% in the group receiving once-weekly IFN beta-1a (p=0.006). The number of patients without new PD/T2 lesions was higher in the group of patients continuously treated with IFN beta-1b standard dose (77%) compared to the once-weekly IFN beta-1a group (23%) (p=0.04). IFN beta is a long-term treatment for MS. The reduction of IFN beta-1b administration frequency and dose is not advisable even in patients free from clinical and MRI disease activity for many years.
Collapse
Affiliation(s)
- Pierangelo Barbero
- Divisione di Neurologia, Ospedale San Luigi Gonzaga, Regione Gonzole, Via Cherasco, 15, 10-I 10043 Orbassano, Turin, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Abstract
Three different interferon beta (IFN beta) products are currently approved for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). However, the recommended method of administration, the dosage and the frequency of administration differ widely between each of the three products. Although controlled clinical trials have demonstrated the efficacy of both alternate-day IFN beta-1b (Betaferon/Betaseron) and once-weekly IFN beta-1a (Avonex) compared with placebo, it is likely that patient compliance, efficacy and tolerability are affected by the dosage regimen used. There are several issues to consider. Once-weekly administration may be associated with fewer adverse events and greater convenience, and it has been suggested that this may increase compliance. Conversely, frequent administration may be associated with increased overall efficacy. There is a convincing pharmacological rationale indicating that frequent dosing, with an interval of less than 72 h, is necessary to sustain the activity of intracellular molecular signalling pathways responsible for regulating IFN beta-induced gene expression. However, there was a need to explore the overall effectiveness of the two administration protocols in a comparative trial. The INCOMIN (Independent Comparison of Interferon) study compared clinical and magnetic resonance imaging (MRI) efficacy of IFN beta-1b 250 microg (8 MIU) subcutaneously (s.c.) on alternate days and IFN beta-1a 30 microg (6 MIU) intramuscularly (i.m.) once weekly in patients with RRMS. INCOMIN demonstrated convincingly that clinical and MRI outcome measures were significantly better in the IFN beta-1b-treated group. Blinded MRI evaluation confirmed the clinical results. Despite some limitations of the study design, imposed by the ethical and practical challenges of conducting comparative trials of injectable therapies, the concordance of the clinical and MRI findings indicate that frequently administered IFN beta-1b reduced evidence of disease activity more effectively than once-weekly administered IFN beta-1a, with the clinical benefits for patients becoming more pronounced over time. Given that the response to IFN beta appears to be dose dependent, the question that might be asked is whether greater efficacy can be obtained by increasing doses beyond those currently approved. OPTIMS (Optimization of Interferon dose for MS) is currently examining the safety and efficacy of a dose of IFN beta-1b that is higher than any currently marketed IFN beta. While OPTIMS is still underway, preliminary safety analyses indicate that higher doses are well tolerated.
Collapse
Affiliation(s)
- Luca Durelli
- Department of Neuroscience, University of Turin, Turin, Italy.
| |
Collapse
|
40
|
Isoardo G, Bergui M, Durelli L, Barbero P, Boccadoro M, Bertola A, Ciaramitaro P, Palumbo A, Bergamasco B, Cocito D. Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features. Acta Neurol Scand 2004; 109:188-93. [PMID: 14763956 DOI: 10.1034/j.1600-0404.2003.00203.x] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVE Thalidomide is a promising therapy for multiple myeloma. Sensory neuropathy is a side effect of thalidomide and resulted to be partially reversible in 50% of cases, suggesting a sensory ganglionopathy. Spinal cord magnetic resonance imaging (MRI) was found to be useful in the diagnosis of sensory ganglionopathies and we use it to determine if thalidomide neuropathy has features of a ganglionopathy. MATERIAL AND METHODS Six patients with multiple myeloma developed thalidomide-induced polyneuropathy. Nerve conduction studies, somatosensory-evoked potentials (SEPs) and cervical and dorsal spinal cord MRI were obtained in all. RESULTS All patients had a sensory neuropathy, with clinical or electrophysiological abnormalities involving all four limbs. Spinal cord MRI showed high signal intensity in the posterior columns in only one patient, with abnormal central conduction time at SEPs. CONCLUSION Our results suggest that thalidomide can induce either an axonal length-dependent neuropathy or, less frequently, a ganglionopathy.
Collapse
Affiliation(s)
- G Isoardo
- Dipartimento di Neuroscienze, Università di Torino, Torino, Italia.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Abstract
Low levels of naturally-occurring, high-affinity antibodies directed against cytokines can be found in the circulation of individuals who have never been exposed to exogenously-supplied cytokines. These antibodies are thought to play a regulatory role in the intensity and duration of immune response. Interferon (IFN) beta has been shown to attenuate both relapsing-remitting multiple sclerosis (MS) and secondary progressive MS in several well-powered, randomized, controlled clinical trials. IFN therapy can induce the production of anti-IFN neutralizing antibodies (NAb), usually in the second 6 months of treatment, in 3 to 45% of treated patients. This variation in the proportion of NAb-positive patients is probably due to the immunogenicity of different formulations of IFN beta, as well as the assay used, which are not currently standardized. The occurrence of NAb appears to be directly correlated with the dose of therapeutic IFN administered, up to a certain dose threshold. If the dose is increased beyond this threshold, the levels of NAb decrease. The biological significance of anti-IFN NAb is not yet known, nor has it been proven conclusively that they affect the clinical response to IFN beta therapy. The presence of NAb is therefore not an indication that treatment should be changed. Indeed, any treatment decision should be based only on the clinical response to therapy.
Collapse
Affiliation(s)
- Luca Durelli
- University Division of Neurology, S. Luigi Gonzaga Hospital, Regione Gonzole, 10, I-10043 Orbassano, Torino, Italy.
| | | |
Collapse
|
42
|
Abstract
Chronic inflammatory demyelinating polyneuropathy (CIDP) is frequently associated with monoclonal gammopathies of undetermined significance (MGUS), Waldenström disease and osteosclerotic myeloma. There are still controversies about the role of these paraproteinaemias in determining the clinical features and the response to treatment of CIDP. We review the clinical, electrophysiological and immunological features and the response to treatment of patients with CIDP associated with paraproteinaemias. The available literature suggest some conclusions: presence of antimyelin-associated glycoprotein (MAG) antibody (Ab) identifies patients with mainly sensory CIDP and low response to treatment; CIDP associated with IgM-paraproteinaemia without anti-MAG Ab probably are similar to CIDP not associated with paraproteinaemia as well as CIDP with IgG- or IgA-MGUS; however, some patients with IgA-MGUS can show features similar to CIDP with IgM paraproteinaemia and anti-MAG Ab. Low response to immunomodulating treatment in patients with mainly motor CIDP should prompt a careful research of an underlying osteosclerotic myeloma.
Collapse
Affiliation(s)
- D Cocito
- Laboratorio di Neurofisiologia Clinica, Dipartimento di Neuroscienze, Università di Torino, Torino, Italy.
| | | | | |
Collapse
|
43
|
Abstract
In one of the most frequent MS demyelination patterns, IgG and complement are demonstrable on myelin surface. It is, probably, an antibody-mediated pattern of myelin damage, usually associated with acute MS, but, at times, observed even in chronic cases. This pattern of myelin damage is extremely similar to that observed in acute demyelinating inflammatory polineuropathies, such as Guillain-Barré syndrome, and in acute disseminated encephalomyelitis (ADEM), a rare demyelinating disease usually occurring after a viral infection or vaccination. These pathologies response well to IgG treatment. Although hyperacute severe cases of MS seem to respond well to IgG treatment, this does not seem the case for other cases of relapses in relapsing-remitting MS. Several trials failed to provide clear evidence of clinical and MRI efficacy of high-dose IgG parenteral treatment in relapsing-remitting multiple sclerosis (MS). The study of Confavreux and the PRIMS study showed that the relapse rate decreases significantly during pregnancy in MS patients, while increases after delivery. IgG is not a cytostatic drug and therefore it has been tested to see whether it reduces relapse occurrence after delivery. In pregnant MS patients treated with high dose, Haas' study and our experience noted a slight increase relapse rate during the six month after delivery but lower than that showed in Confavreux and PRIMS studies in untreated pregnant MS women.
Collapse
Affiliation(s)
- L Durelli
- Dipartimento di Neuroscienze, Università di Torino, Torino, Italy
| | | | | |
Collapse
|
44
|
Barkhof F, Rocca M, Francis G, Van Waesberghe JHTM, Uitdehaag BMJ, Hommes OR, Hartung HP, Durelli L, Edan G, Fernández O, Seeldrayers P, Sørensen P, Margrie S, Rovaris M, Comi G, Filippi M. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. Ann Neurol 2003; 53:718-24. [PMID: 12783417 DOI: 10.1002/ana.10551] [Citation(s) in RCA: 98] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
In the recently proposed diagnostic criteria for multiple sclerosis (MS) by McDonald, the modified magnetic resonance imaging (MRI) Barkhof criteria have been incorporated. We examined the validity of this implementation in the Early Treatment of MS study, a randomized, double-blind, placebo-controlled study of 22 microg interferon beta1a given subcutaneously once weekly in 309 patients with a first episode consistent with demyelinating disease (and abnormal MRI). Conversion to clinically definite MS (CDMS) within 2 years of follow-up, as evidenced by a new clinical episode, occurred in 41% of patients (independent of treatment) with gadolinium enhancement or nine or more T2 lesions versus 11% of those without either finding (p = 0.017); similarly, proportions converting were 44% versus 31% for infratentorial lesions (p = 0.026), 40% versus 35% for juxtacortical lesions (p = 0.413), and 41% versus 17% for three or more periventricular lesions (p = 0.034). The rate of conversion to CDMS based on the number of modified Barkhof criteria was 22% for two or fewer positive criteria, increasing to 47% with four positive criteria. For a cutoff of three positive criteria, the hazard ratio for time to CDMS was 2.3 (95% confidence interval, 1.17-4.55; p = 0.016). Treatment effect seemed more evident as the number of positive criteria increased, and the number of patients needed to avoid one patient converting to CDMS decreased from 50 in patients with one or two positive criteria to 5.6 in patients with four positive criteria. However, the study was not powered to detect statistically significant treatment by variable interaction, and this remains an important issue for further study.
Collapse
Affiliation(s)
- Frederik Barkhof
- MS-MRI Centre and Department of Radiology, VU Medical Centre, Amsterdam, The Netherlands.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Durelli L, Verdun E, Barbero P, Bergui M, Versino E. Re: Vartanian T. An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of interferon beta products in the treatment of multiple sclerosis. Clin Ther. 2003;25:105-118. Clin Ther 2003; 25:1890-3. [PMID: 12868445 DOI: 10.1016/s0149-2918(03)90054-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
46
|
Cocito D, Ciaramitaro P, Isoardo G, Barbero P, Pipieri A, Poglio F, Durelli L. Abstracts of the 8th Meeting of the Italian Peripheral Nerve Study Group: 56. J Peripher Nerv Syst 2003. [DOI: 10.1046/j.1529-8027.2003.00056.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
47
|
Cocito D, Isoardo G, Ciaramitaro P, Migliaretti G, Cavallo F, Rota E, Poglio F, Durelli L, Bergamasco B. Abstracts of the 8th Meeting of the Italian Peripheral Nerve Study Group: 55. J Peripher Nerv Syst 2003. [DOI: 10.1046/j.1529-8027.2003.00055.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
48
|
Cocito D, Ciaramitaro P, Isoardo G, Barbero P, Migliaretti G, Pipieri A, Proto G, Quadri R, Bergamasco B, Durelli L. Intravenous immunoglobulin as first treatment in diabetics with concomitant distal symmetric axonal polyneuropathy and CIDP. J Neurol 2002; 249:719-22. [PMID: 12111305 DOI: 10.1007/s00415-002-0698-0] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The authors investigated the impact of IVIg as first line treatment of diabetic patients suffering from chronic inflammatory demyelinating polyneuropathy (CIDP) concomitant with distal symmetric axonal polyneuropathy. Nine patients with these clinical and electrophysiological features were treated with IVIg (0.4 g/Kg/day for 5 days). Clinical and electrophysiological evaluations were performed before and after treatment. Following IVIg treatment there was no significant improvement in clinical deficit. However, there was a significant and persistent decrease in the Rankin scale score and an improvement in the demyelinating feature on nerve conduction studies. Our findings suggest that IVIg had small but detectable beneficial effects on diabetic patients with CIDP and a high degree of axonal damage.
Collapse
Affiliation(s)
- Dario Cocito
- U. O. A. D. U. Neurologia I, Dipartimento di Neuroscienze, Università di Torino, Via Cherasco 15, 10126 Turin, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Limone P, Ferrero B, Calvelli P, Del Rizzo P, Rota E, Berardi C, Barberis AM, Isaia GC, Durelli L. Hypothalamic-pituitary-adrenal axis function and cytokine production in multiple sclerosis with or without interferon-beta treatment. Acta Neurol Scand 2002; 105:372-7. [PMID: 11982488 DOI: 10.1034/j.1600-0404.2002.01155.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
OBJECTIVES Pro-inflammatory cytokines mediate brain damage in multiple sclerosis (MS); they can also influence the hypothalamic-pituitary-adrenal (HPA) axis function. We evaluated the possible abnormalities of HPA axis function in relapsing-remitting MS (RR-MS). MATERIAL AND METHODS IFN-gamma, TNF-alpha and IL-6 production by ex-vivo lymphocytes from 10 normal volunteers and 10 RR-MS patients before and during IFN-beta therapy was assessed; pituitary-adrenal function was evaluated by means of CRH and ACTH stimulation tests. RESULTS In untreated patients the production of IFN-gamma, TNF-alpha, IL-6 was increased, and was significantly decreased by IFN-beta. Neither basal, nor stimulated ACTH, cortisol, DHEA, DHEAs, 17-alpha-OH-progesterone levels differed between controls and RR-MS patients, both before and during treatment. Moreover, no correlation was found between endocrine and immune parameters. CONCLUSION In MS the HPA axis function seems normal and not influenced by IFN-beta treatment. This result is discussed in relation to the increased production of pro-inflammatory cytokines found in this disease.
Collapse
|
50
|
Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, Montanari E, Zaffaroni M. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359:1453-60. [PMID: 11988242 DOI: 10.1016/s0140-6736(02)08430-1] [Citation(s) in RCA: 355] [Impact Index Per Article: 16.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
BACKGROUND The three interferon beta preparations approved for treatment of relapsing-remitting multiple sclerosis (MS) differ in dose and frequency of administration. Interferon beta-1a 30 microg is administered once a week, interferon beta-1a 22 microg or 44 microg is given three times a week, and interferon beta-1b 250 microg is administered on alternate days. No clinical study directly comparing the different regimens has been published. The INCOMIN study was designed to compare the clinical and magnetic resonance imaging (MRI) benefits of on-alternate-day interferon beta-1b 250 microg with once-weekly interferon beta-1a 30 microg. METHODS INCOMIN was a 2-year, prospective, randomised, multicentre study. 188 patients with relapsing-remitting MS were assigned to interferon beta-1b (n=96) or interferon beta-1a (n=92). Primary outcome measures were the proportion of patients free from relapses and that of patients free from new proton density/T2 lesions at MRI assessment. Several secondary outcome measures were also assessed. Analysis was by intention to treat. FINDINGS Over 2 years, 49 (51%) individuals administered interferon beta-1b remained relapse-free compared with 33 (36%) given interferon beta-1a relative risk of relapse 0.76; 95% CI 0.59-0.9; p=0.03); and 42 (55%) compared with 19 (26%), respectively, remained free from new T2 lesions at MRI (relative risk of new T2 lesion 0.6; 0.45-0.8; p<0.0003). In both groups, the differences between the two treatments increased during the second year. There were also significant differences in favour of interferon beta-1b in most of the secondary outcome measures, including delay of confirmed disease progression. INTERPRETATION High-dose interferon beta-1b administered every other day is more effective than interferon beta-1a given once a week.
Collapse
|